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Abstract

Cyclin-dependent kinases (Cdks) control progression through the cell cycle. Proper
regulation of the events associated with each phase is critical for the cellular response to
alterations induced by intrinsic and extrinsic signals. The requirement for tight, and
highly-ordered control of the cell cycle is evident given the multi-mechanistic regulation
of Cdks. Positive stimulation of Cdks is regulated by several means, such as activation by
phosphorylation and interaction with cyclin proteins expressed only at specific times
during the cell cycle. Negative regulation of Cdk activity involves interaction with Cdk
inhibitors and modification at inhibitory residues. It is noteworthy, however, that
regulation of Cdk activity is not exclusively accomplished through these mechanisms. The
speedy/RINGO family of proteins is uniquely capable of activating Cdk1 and 2 in the
absence of positive regulation. The originally identified human homolog of this family,
Spy1, is expressed in a variety of human tissues and found at elevated levels in several
human cancers. Abnormally elevated Spy1 bypasses checkpoint activation and suppresses
apoptosis. A detailed understanding of how Spy1 is regulated is required to determine the
contribution of Spy1 in normal cell cycle progression and cellular homeostasis. Here, I
demonstrate that Spy1 is selectively regulated as part of the cellular response following
DNA damage. Degradation of Spy1 depends on Chk2 and p53, and appears to occur via
the ubiquitin/proteasome system. Moreover, Spy1 expression bypasses UV-induced
premature senescence as well as replicative-induced senescence in the presence of p53 and
p21. Knock-down of endogenous Spy1 accelerates the onset of senescence, suggesting a
functional role for Spy1 in the regulation of cellular senescence. Furthermore, our work
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reports a unique mechanism of Cdk activation, in which Spy1 interacts with the Cdk2/p21
complex, promotes degradation of p21, and subsequently activates Cdk2. This level of cell
cycle regulation may be explained as a “back-up” mechanism for cells to tolerate the
alterations induced by various stimuli.
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Chapter 1: General Introduction

1

1.1 DNA damage response network
DNA is subject to a constant barrage of both endogenous and exogenous
genotoxic insults. Environmental DNA damage can be induced by physical or chemical
sources, such as ionizing radiation (IR), ultraviolet radiation (UV), and chemotherapeutic
drugs. Reactive oxygen species created by cellular metabolic processes and replication
errors represent other sources of these insults. To ensure genomic stability, cells have
evolved a network of signaling pathways, referred to as the DNA damage response
(DDR). The DDR can trigger “checkpoint” responses in mutated cells to slow or halt
their normal cycling behavior and allow for the damaged DNA to be repaired [1]. When
the DDR fails to perfectly reverse the damage, or in cases of sustained and/or extensive
genetic damage, corrupted cells are eliminated by senescence or apoptosis (programmed
cell death). Deficiencies in the DDR can cause substantial genomic instability, a hallmark
of cancer cells.
1.2 UV irradiation
UV irradiation spectra are divided into three wavelength groups: UVA (320-400
nm), UVB (290-320 nm) and UVC (200-290 nm). By possessing shorter wavelengths and
higher energy, UVB and UVC can facilitate photochemical reactions between DNA bases
forming cyclobutane pyrimidine dimers (CPDs) [2,3] and pyrimidine-(6-4)-pyrimidone
photoproducts ((6-4)-PPs) [4], which are deleterious to cells. While CPDs have a modest
effect on DNA structure and do not significantly affect the ability of the two pyrimidines
to form a Watson-Crick base pair with the correct purine base, (6-4)-PPs induce a large
structural alteration in DNA [5-8]. C→T (cytosine to thymine) transitions within
pyrimidine dinucleotides can be induced by both CPDs and (6-4)-PPs [9]. In mammalian

2

cells, UV-induced CPDs, the most abundant DNA lesions induced by UV, and (6-4)-PPs
are removed via nucleotide excision repair (NER), either by transcription-coupled repair
(TCR) or global genomic repair (GGR) [10]. However, (6-4)-PPs are rapidly and
efficiently removed, whereas CPDs are repaired rather slowly and incompletely, inducing
the majority of the UV-induced mutations in our cells [9]. If not removed, these bulky
photo-lesions prevent progression of the replication fork and consequently inhibit
DNA/RNA polymerases, leading to arrested polymerization. Unresolved stalled
replication forks may collapse and cause formation of DNA double strand breaks (DSBs)
[11]. In addition to these lesions, modified bases and single strand breaks (SSBs) are
other types of damage induced by UV. Although UVA is known to be least harmful,
there is increasing evidence suggesting that UVA has genotoxic effects on cells as well
[12-15]. Radiation-induced DNA lesions signal the DDR; the nature and extent of the
response are dose- and cell-type dependent. For instance, the DDR in terminally
differentiated cells favors activation of DNA repair to defend the integrity of their
genome [16]. Proliferating cells, on the other hand, activate cell cycle checkpoints to
invoke arrest. Cells exposed to low doses of UV consider activation of repair mechanisms
while higher doses of UV trigger apoptosis [17].
Alteration in the structure of DNA, caused by UV, can be detected by multisubunit protein complexes, generally classed as “sensor” proteins. Sensor proteins
function to recruit and activate proteins to the site of damage that are broadly termed
“mediator” proteins. The mediator proteins, in turn, activate “transducer” proteins, which
are capable of amplifying the damage signal by activating specific “effector” proteins.
This cascade of events ultimately accomplishes a precise and appropriate physiological
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response by inducing cell cycle arrest or repair [18]. Should the damage be irreversible,
permanent arrest (senescence) or death (apoptosis) will occur (see Figure 1.1). While the
independent functions of the proteins involved in the DDR have in large part been
elucidated, identifying how these components communicate to one another remains
challenging due to the growing complexity of this network.
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Figure 1.1 A generic representation of the D
DNA damage response pathway.
pathway
Following DNA alterations
alterations, translocation of the sensors molecules recruits mediators
mediato to
the site of damage. These
These, consequently, induce activation of the transducers and their
downstream effectors to rapidly initiate tthe
he processes of cell cycle arrest,
arrest repair,
senescence or apoptosis.
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1.3 DNA damage sensors
The proteins that primarily sense the changes in DNA structure, and consequently
trigger the DDR, are known as DNA damage “sensors”. These proteins must have the
ability to directly/physically recognize the break, bind to broken DNA strands and be
activated by them [18]. Amongst the potential sensor candidates, the MRN complex that
displays direct binding to DSBs [19], and RPA that signals the recruitment of other
single-stranded DNA sensors such as 9-1-1 complex and ATRIP
, are of particular interest [20]. These sensor complexes elicit the checkpoint response by
activating a cascade of downstream events, leading to induction of the appropriate
cellular response.
1.3.1 MRN complex
The MRN complex is comprised of three proteins: Mre11, Rad50 and Nbs1. Null
mutations of any of the genes involved in this complex causes embryonic lethality in
mice, emphasizing the indispensability of the MRN complex [21,22]. Within minutes of
induction of DSBs, Mre11 protein, which is distributed in the nucleus in complex with
Rad50 protein, migrates to the DSBs [23] and forms a hetero-tetrameric assembly
(M2R2) [24]. The complex of Mre11 and Rad50 tethers the broken DNA ends via long
coiled-coil domains of Rad50 protein, and possesses ATP dependent endo- and exonucleolytic activities [25,26] that are important for DNA double strand break resection
[27]. Interaction of Nbs1 with Mre11 provides a completely functional complex [28].
Through its C-terminal interaction domains, Nbs1 associates with the downstream
signaling molecule, ATM (described later), to promote its localization to broken ends,
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yielding fully activated protein capable of passing the signal on to its downstream
signaling molecules [29].
1.3.2 RPA, ATRIP, and 9-1-1 complex
Single stranded DNAs (ssDNAs) formed during replication and the processes of
repair, or those formed by resection of the ends of DSBs, initiate a signal to recruit the
ssDNA-binding complex, replication protein A (RPA), to coat and stabilize the ssDNA
[30]. Once RPA is tightly bound to ssDNA lesions, it independently brings two other
sensor complexes to the sites of damage [31]. The hetero-trimeric 9-1-1 complex (Rad9,
Rad1, and Hus1) is loaded onto the RPA-coated ssDNA by the clamp loader, Rad17-RFC
(replication factor C), which is comprised of Rad17 and subunits 2 to 5 of the RFC
complex [31-33]. RPA also recruits ATRIP (ATR interacting protein), which acts as
another sensor of the DNA damage. Once both complexes are loaded, the link between
the two is provided through DNA topoisomerase II binding protein 1 (TopBP1), which
interacts with Rad9 and ATRIP [34-37]. This interaction activates the downstream
signaling protein, ATR (discussed later), to phosphorylate its numerous targets [38].
1.4 DNA damage mediators
Downstream from the damage sensors, other DNA damage signaling molecules
are sequentially recruited to DNA breaks. Activated at very early stages of the DDR
pathway, ATM (ataxia-telangiectasia mutated) and ATR (ATM- and Rad3-related) are
the “mediators” of the DDR [18]. Despite being members of the phosphoinositol-3kinase-like kinase family (PIKK), ATM and ATR function as serine/threonine kinases.
ATM responds primarily to double-strand breaks induced by ionizing irradiation (IR),
while ATR is essential in the response triggered by stalled replication forks occurring due

7

to UV irradiation or hydroxyurea [39]. Although ATM and ATR are not fully redundant,
they share substantial overlap in the targets that they phosphorylate. Research focused on
the overlapping functions of ATM and ATR has provided evidence, which challenges the
classic view that these kinases respond to distinct stimuli. For instance, recruitment and
activation of ATR in late-S and G2 phases in response to IR requires functional ATM,
Nbs1 and Mre11 [40]. Furthermore, ATM is also required for the repair of damage
induced by UV irradiation [41]. ATM is activated in response to UV or stalled replication
fork induced by hydroxyurea [42].
Fully understanding the interplay between these kinases and their distinct
functions will be accomplished by specifying their respective targets in response to
specific types of damage.
1.4.1 ATM
A-T, Ataxia-Telangiectasia, is an autosomal recessive syndrome involving
multisystems throughout its development, including nervous, immune, and reproductive
systems [43]. A-T patients show complex phenotypic characteristic such as genomic
instability, cerebellar degeneration, immunodeficiency, predisposition to cancers such as
leukemias and lymphomas, premature aging, and radio-sensitivity, which is a hallmark of
this disease [43-46]. In 1995, the cause of A-T was found to be a mutation in a gene
named ATM, ataxia telangiectasia-mutated [47]. Cells from A-T patients were extremely
sensitive to ionizing radiation, which later suggested a role for ATM in the DDR.
The ATM gene encodes a 3056-amino acid protein with a molecular weight of 350
kDa and is conserved across eukaryotes. In response to DSBs, inactive ATM dimers or
multimers dissociate into active monomers following auto-phosphorylation at serine 1981
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[48]. Later biochemical studies, however, have shown that in vitro activation of ATM can
be achieved in the absence of auto-phosphorylation serine 1981 [28,49]. Moreover,
mouse models with mutated ATM auto-phosphorylation sites lacked any detectable
defect in ATM function [50,51], suggesting that auto-phosphorylation of ATM is not the
primary mechanism for ATM activation. Full activation and recruitment of ATM to the
site of damage involves the contribution of the primary DNA damage sensor, MRN
complex. Biochemical studies have established that MRN is sufficient to induce the
kinase activity of ATM in vitro [28,49,52], indicating that MRN is essential for the full
activation of ATM. In addition to auto-phosphorylation and interaction with MRN, more
recent works have demonstrated a direct role for the ubiquitously expressed histone
acetyltransferase Tip60 in ATM activation [53,54]. Following DNA damage, Tip60
interacts with histone H3 trimethylated on lysine 9, which induces the acetyltransferase
activity of Tip60 [55]. Rapidly activated Tip60 forms a complex with ATM [53,56],
leading to the acetylation of lysine 3016 of ATM by Tip60 and activation of the ATM
kinase [53,56,57]. Loss of Tip60 activity, or mutation of lysine 3016, prevents ATM
acetylation and blocks its activation, indicating a crucial role for Tip60 in ATM
activation [57]. Activated ATM then phosphorylates the substrates involved in the DDR,
including Chk2 [58], p53 [59,60], and H2AX [61] (see Figure 1.2).
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Figure 1.2 Activation of ATM.
Recruitment of MRN complex to DSBs leads to formation of monomeric ATM from its
original inactive homodimer state. Further activation of monomerized ATM
phosphorylates H2AX. In turn, phosphorylated H2AX recruits additional MRN/ATM
complexes and further H2AX phosphorylation. By phosphorylation of its downstream
substrates, especially Chk2, ATM initiates a signal that leads to inhibition of origin firing,
cell cycle arrest, and DSB repair.
(Reproduced with permission from [62])
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1.4.2 ATR
In humans the most closely related member of the PIK-related kinase family to
ATM is the ATR protein, which was discovered in a genome search (using a Jurkat T-cell
cDNA library) for homology to the ATM gene [63]. Independently, human ATR gene was
found as an orthologue of rad3 gene of Schizosaccharomyces pombe [64]. Unlike other
PIKK family members, ATR is essential for early embryonic development [65,66]. This
essentiality reflects the ATR function in regulation of p53 during checkpoint activation,
and also its role in the regulation of DNA replication in S phase of the cell cycle [67].
Lower levels of ATR kinase activity, due to altered splicing of the ATR gene, has been
reported in some cases of Seckel syndrome individuals [68].
ATR is a 2644 amino acid protein with an unusually large size of 301 kDa. In
proliferating cells, ATR is preferentially activated during DNA replication blocks
induced by UV irradiation [69], hydroxyurea [70], aphidicolin [70,71] and DNAalkylating agents [72]. By formation of stalled replication forks, ATR, bound to its
interacting partner ATRIP [73], is recruited to ssDNAs coated with RPA [74]. Following
the independent recruitment of the 9-1-1 complex by RPA, TopBP1 links the two
complex through its interaction with ATRIP and Rad9. This linkage facilitates further
activation of ATR. Claspin, a co-mediator in activation of Chk1, binds to Chk1 and
translocates Chk1 to the sites of damage. There, Claspin binds to Rad9 and ATR and
makes Chk1 an accessible target for ATR phosphorylation [75-77]. As the primary target
of ATR, phosphorylation of Chk1 on serines 317 and 345, directly, leads to the activation
of Chk1 [38,78,79]. Among many of the ATR targets are proteins such as H2AX [80] and
p53 [81] (see Figure 1.3).
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Figure 1.3 Activation of ATR.
ssDNA coated with RPA recruits both ATR-ATRIP and 9-1-1 complexes, independently.
RPA binding to ATRIP facilitates recruitment of the 9-1-1 trimer by the clamp loader,
Rad17–RFC complex. Consequently, through an interaction between Rad9 and the ATR
activator, TopBP1, ATR actively phosphorylates its targets, Chk1 in particular.
Following phosphorylation of the ATR effectors, inhibition of origin firing, cell cycle
arrest, and stabilization of stalled replication forks take place.
(Reproduced with permission from [62])
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1.5 DNA damage transducers
The key signal transducers of DNA damage are Chk1 and Chk2. Upon exposure
to DNA damage, ATM and ATR phosphorylate and activate Chk2 [58] and Chk1
[38,78,79], respectively, to convey the signal in damaged cells. Chk1 and Chk2 are
structurally unrelated serine/threonine kinases [82]. They share substrate specificity but
are not functionally redundant kinases [83]. Their recruitment by the mediators, ATM
and ATR, to sites of damage facilitates transduction of the signal to the downstream
effector proteins.
1.5.1 Chk2
Chk2 is a relatively stable protein expressed ubiquitously in all phases of the cell
cycle, but in an inactive form [84]. Mainly in response to DSBs, Chk2 appears to be
phosphorylated by ATM at threonine 68 residue [85]. This trans-phosphorylation primes
intermolecular trans-phosphorylation at threonines 383 and 387 and homo-dimerization
of Chk2, which regulates its activation [86]. Although cells lacking Chk2 can survive,
they show defective checkpoint signaling [87]. Inactivation of Chk2 in humans leads to
Li-Fraumeni syndrome, suggesting a tumor suppressive function for this protein [88].
1.5.2 Chk1
Chk1 is expressed during S and M phases of the cell cycle in normal cells, with
detectable kinase activity [89]. High levels of Chk1 in G1 arrested cells have also been
reported, indicating its role in G1 arrest [90]. In response to DNA damage or replication
fork block, phosphorylation of Chk1 at serines 317 and 345 by ATR, or ATM in response
to DSBs, leads to its further activation [79]. Deletion of CHEK1 has been shown to be
embryonic lethal [91].
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1.6 DNA damage effector protein p53
The protein p53 was originally described in 1979 [92-95]. It migrated as a 53 kDa
protein in SDS-PAGE and it was thought to be involved in cell transformation and
considered as an onco-protein [77-80]. Later, it became evident that mutant protein
contributed to cell transformation, while the wild-type p53 protein had tumor suppressive
function [96-100]. Studies over the years have shown that in more than 50% of human
cancers p53 is mutated [101]. Most of the p53 mutations found in cancers are located
within the central DNA-binding domain [102]. The human p53 protein, with 393 amino
acids, is comprised of four conserved domains: the trans-activation domain (residues 142) [103], the proline-rich domain (residues 64-92) [104], the sequence specific DNAbinding domain or core domain (residues 102-292) [105], and the oligomerization
domain (residues 319-360) [106]. In normal unstressed cells, p53 is an unstable protein
and present at very low cellular levels [107], owing to continuous binding to its specific
E3 ubiquitin ligase Mdm2 (murine double minute 2), which controls its degradation
[107]. Mdm2 binds within the trans-activation domain of p53 and reduces the ability of
p53 to activate gene expression [108,109]. DNA damage and other stress signals trigger
an increase in the stability of p53 by perturbing its binding to Mdm2 [93,94,95].
Additionally, stress induces the element of post-translational modification. ATM, ATR,
Chk1, and Chk2 can phosphorylate p53 at critical sites [59,60,110,111]. Multi-site
phosphorylation of the p53 transcription factor not only supplements its dissociation from
Mdm2 [95], but also regulates its transcriptional activating function [112-117]. Although
the DNA-binding domain mediates specific p53 binding to its target genes,
tetramerization of the protein via its oligomerization domain is required for formation of
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p53/DNA complex and, subsequently, transactivation of its target genes [118-120]. It is
estimated that expression of 200-300 genes might be regulated by p53 [121]. Amongst
transcriptional targets of p53, p21 [122], Gadd45 [123], and 14-3-3δ [124] are involved
in cell cycle control.
p53 belongs to a family of proteins that includes two structurally related proteins,
p63 (p40, p51) [125] and p73 [126]. p63 and p73 proteins share high sequence similarity
and conserved functional domains [127]. They exert p53-like properties and are
competent to transactivate p53 target genes, suppress cell growth, and induce apoptosis
[128,129]. Three different isoforms of the p63 protein (α, β and γ) differ at the
transactivation domain, TA-p63TA and ∆N-p63. While the TA-p63 isoforms act as
transcription factors, the ∆N-p63 isoforms, which lack the main trans-activation domain,
act as dominant-negative inhibitors of TA isoforms [130]. The ∆N isoforms of p63 can
also act in a dominant-negative manner towards p53 [128]. Similar to p53, p73
accumulates in response to DNA damage, which is mediated by Chk1 and Chk2 kinases
to induce apoptosis [131]. Although p73 is not inactivated in human tumors as often as
p53, it has been suggested to be a tumor suppressor protein [132].
1.7 DNA damage-induced cell cycle checkpoints
Checkpoint signaling pathways induced by DNA damage can halt cell cycle
progression in any phase of the cell cycle to limit genomic instability. DNA damageinducing agents such as UV light can potentially arrest the cells at the G1, S, and G2
phases of the cell cycle. While G1 and G2 checkpoints prevent cell cycle progression to
block cells from experiencing DNA replication or mitosis, the intra-S phase checkpoint
induced by UV is sensitive to transient reductions in DNA synthesis induced by
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checkpoint signaling pathways [133]. Although distinctive, these checkpoints share
similarities; they must be activated by DNA damage (DNA damage-induced cell cycle
checkpoints), and make use of many of the same proteins.
Generally, checkpoints and their regulation of the cell cycle are well conserved
from yeast to human; these checkpoints are all mediated by the activity of protein kinases
and phosphatases. Post-translational modifications, e.g., phosphorylation events, allow
rapid transition of signal, transduction or termination. By means of such a highly rapid
regulatory approach, cells promptly respond to damage, as it is pivotal to the survival of
the damaged cell.
1.7.1 G1 phase progression and DNA damage-induced G1 checkpoint
At a key regulatory site in G1, termed the “restriction point”, cells respond to the
stimulation from appropriate growth factor signals. By transiting the “restriction point”,
at the heart of or late in G1 phase, cells make critical decisions about their fate; they are
either destined to enter S phase and commit to replicate their DNA or withdraw from the
cycle [134]. Once past the restriction point, return is impossible. However, activation of
checkpoints can modulate any further progression even when cells have already passed
the commitment point, although not sufficiently prolonged. Therefore, not only can the
cell cycle be blocked at the restriction point in G1, but also at later points in the G1/S
boundary.
As key regulators of cell cycle progression, cyclins share a significant role in
checkpoint signaling. Two major classes of G1 cyclins, D and E types, interact with
either Cdk4 or Cdk6, and Cdk2, respectively. Initial expression of cyclin D in response to
stimuli provides a partner for Cdk4/6 [135,136]. Active complexes of cyclin D/Cdk4/6
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kinases phosphorylate the retinoblastoma (Rb) tumor suppressor [137-141]. Hypophosphorylated Rb is capable of associating with members of E2F family, which further
prevents them from activating their target genes that are critical for progression into S
phase [142,143]. As cyclin D levels increase, Rb becomes phosphorylated to an extent
where it can dissociate from E2F. As a result of this release, cyclin E becomes detectable,
and complexes with Cdk2 to fully phosphorylate Rb [144]. Hyper-phosphorylation of Rb
further disrupts association of Rb with E2F [144]. Not only are activating partners of
Cdks involved in the regulation of the cell cycle, but the inhibitors of these kinases also
play an important role. The p21 and p27 proteins are members of the CIP/KIP family of
cyclin-dependent kinase inhibitors (CKIs), which are well known for their negative
regulation of the cell cycle [145]. CKIs can assemble with cyclin E/Cdk2 and suppress
the activity of the complex [146,147]. By increased binding of cyclin D to Cdks, in
response to mitogenic stimuli, cyclin D/Cdk4/6 complexes that are accumulating
sequester the CKIs. Through release of the inhibitors, cyclin E/Cdk2 complexes retain
their activity, which can further modify Rb to its hyper-phosphorylated form [144],
allowing transcription of the genes involved in S phase progression (see Figure 1.4).
In response to stress-induced damage, molecular mechanisms associated with
DNA damage checkpoints target the main regulatory pathways of the cell cycle. In the
G1 phase of the cell cycle, arrest is accomplished by silencing the activities of cyclin/Cdk
complexes. Cyclin D/Cdk4/6 complex normally lowers the negative regulation of cell
cycle progression by RB in early G1 while cyclin E/Cdk2 complex is the master regulator
of S phase entry. Upon sensing DNA damage, a cell’s response is geared towards
accumulation and activation of the tumor suppressor p53 [148]. Activated p53 that is
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bound to DNA can transcribe a large number of genes whose products are selectively
involved in different pathways triggered by DNA damage. Among these products with
regard to G1 checkpoint is the Cdk inhibitor p21 (CIP1/WAF1) [146,149-152]. In normal
cells the levels of p21 are relatively low, but its elevated expression by p53 provides a
tolerable threshold for cells to suppress the activity of cyclin E/Cdk2 later in G1;
therefore, preventing any further progression (see Figure 1.4).
The mode of action by which p53 employs its role in the regulation of the G1
checkpoint is through multiple steps. This regulation involves post-translational
modification of the p53 protein itself to become fully activated, which is then followed
by transcription and synthesis of its downstream targets. Although this type of response
provides a delayed yet sustained arrest, it does not satisfy the primary need of cells in the
face of damage. Cells have evolved in a way that they react rapidly to cellular stresses.
This additional layer of protection is developed through pathways independent of timeconsuming mechanisms.
Inhibitory regulation of cyclin/Cdk complexes not only occurs by their association
with CKIs, but also through the inhibitory phosphorylation of Cdks at specific sites,
specifically at threonine 14 and tyrosine 15 [153]. In unperturbed cells, the members of
the Cdc25 (cell division cycle 25) family of phosphatases (Cdc25A, Cdc25B, and
Cdc25C) remove the inhibitory phosphate groups, which leads to activation of cyclin/Cdk
complexes [154]. By activating the G1 checkpoint, phosphorylation of Cdc25A on
multiple sites stimulates ubiquitination and proteolysis of the protein [155]. Degradation
of Cdc25A preserves the inhibitory phosphorylation of Cdk2 kinase to effectively inhibit
the cyclin E/Cdk2 activity and progression to S phase. This rapid signaling cascade is
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initiated by the kinase activity of Chk2 [156], and to a lesser extent, by Chk1 [157], as the
direct substrates of ATM and ATR [158], respectively (see Figure 1.4).
Whereas ATM/Chk2 and ATR/Chk1 [159] pathways mediate the initial transient
response via fast turnover of Cdc25A, they also govern the sustained arrest in G1 by
modulating p53 stability. Treatment of cells with ionizing radiation or UV irradiation
triggers phosphorylation of serine 15 residue in the amino terminal region of p53, which
is dependent on ATM or ATR [59,81,160,161], and required for p53 activation
[59,60,162]. Moreover, Chk1 and Chk2 can induce phosphorylation of p53 at multiple
sites, specifically serine 20 [163]. Initial modifications of p53, in the N-terminus of the
protein, supplies partial activation of the transcription factor allowing p53 to activate its
target genes. Alternatively, by targeted phosphorylation of the negative regulator of p53,
Mdm2, ATM and Chk2 can stabilize p53 [164]. Accumulation of p53 and its activation
initiate transcription and expression of a panel of its effector genes, including p21.
Consequently, p21 binds to and disrupts the cyclin E/Cdk2 complex, thereby maintaining
the G1 arrest (see Figure 1.4).
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Figure 1.4 G1 phase and G
G1 checkpoint signaling.
Stimulation of Cdk4/6 kinases, by their interaction with cyclin D,
D creates active
complexes capable of phosphorylat
hosphorylating Rb, resulting in the initial release of
o the E2F.
Later in G1, active E2F
F transcriptionally up
up-regulates cyclin E, which forms an active
complex with Cdk2 to further stimulate E
E2F release, and progression to S phase.
phase After
induction of DNA damage
damage, two checkpoint pathways target
rget the activity of cyclin/Cdk
complexes. The more rapid pathway acts through phosphorylation and inactivation of
Cdc25A
A phosphatase via Chk
Chk2 to inhibit the activation of cyclin E/Cdk
Cdk2 complex, and
any further cell cycle progression
progression. In parallel, stabilization and activation of p53 induces
expression of p21, which binds and inhibits the ccyclin/Cdk complexes, enforcing a more
delayed but sustained arrest
arrest. P: phosphorylation.
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1.7.2 G2 phase progression and DNA damage-induced G2 checkpoint
Faithful transmission of genetic material from one cell to the next generation in M
(mitosis) phase of the cell cycle is decided during the preparation time in G2 phase.
Permission for entering into, and progression through, mitosis is granted primarily by the
mitotic Cdk, Cdk1 (Cdc2, p34). Cdk1 is expressed ubiquitously throughout the cell cycle;
hence, its activity must be controlled at a different level than expression. Similar to the
other Cdks, modifications of the protein on critical residues [165-168] and regulation of
its cyclin binding [169] and inhibitory partners [170] regulate the activity of Cdk1.
Throughout G1 and S phases of the cell cycle, Cdk1 is kept inactive by phosphorylation
on the conserved inhibitory residues, threonine 14 [168,171] and the adjacent tyrosine 15
[165,166] catalyzed by the Myt1 [172] and Wee1 [173] kinases, respectively.
Phosphorylation at either or both of these inhibitory sites suffices to abolish the activity
of the cyclin/Cdk complex [174]. At the end of S phase, expression of the positive
regulatory subunit of Cdk1, cyclin B, leads to formation of cyclin B/Cdk1 complex
(MPF; mitosis/maturation promoting factor) [169]. However, after the formation of the
newly formed cyclin/Cdk complex, inactivation of the complex is maintained by the
presence of inhibitory phosphorylation of threonine 14 and tyrosine 15 on Cdk1
[175,176]. These residues are located in the ATP-binding cleft of Cdk1; therefore, their
phosphorylation leads to the loss of the kinase activity of the Cdk by inhibiting ATP
binding [177,178]. De-phosphorylation of these sites, accomplished by the phosphatase
activities of Cdc25A, Cdc25B and Cdc25C, allows activation of cyclin B/Cdk1 complex
[154,179-185]. Cdc25A which was thought to regulate the G1 to S transition only,
appears to be essential for the entry into and maintenance of M phase, similar to its
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family members Cdc25B and Cdc25C [186]. Throughout G1 and S phases, Cdc25C is
kept inactive through phosphorylation and sequestered in the cytoplasm to prevent
premature activation of cyclin B/Cdk1 complexes [187-189]. Removal of inhibitory
phosphorylations, as well as phosphorylation of activating residues in G2, promotes
activation and localization of Cdc25C to the nucleus [189]. Once activated, Cdc25C dephosphorylates threonine 14 and tyrosine 15, allowing for the activation of cyclin B/Cdk1
[182,185]. Acting in opposition to each other, Wee1/Myt1 and Cdc25C activities must be
tightly controlled throughout the cell cycle. It appears that the regulation of these
enzymes follows similar mechanisms, but consistent to their roles in activation of the
mitotic kinase Cdk1, their activities are in opposition to each other [190]. Active cyclin
B/Cdk1 phosphorylates both Wee1 and Cdc25C; however, phosphorylation of Wee1
inactivates the kinase and sequesters it to the cytoplasm while phosphorylation of
Cdc25C activates the phosphatase to further remove the inhibitory phosphate groups.
This forms a feedback loop in which Cdk1 and Cdc25C activate one another [190-193].
Another control mechanism for the activity of cyclin B/Cdk1 complex is through the
translocation of the complex between the cytoplasm and nucleus [194,195]. Cyclin
B/Cdk1 is mainly located in the cytoplasm during interphase; however, initial activation
of the complex in the cytoplasm in G2 triggers rapid nuclear import of the cyclin B/Cdk2
complex and its accumulation in the nucleus to mediate its activity at mitotic entry [196].
Late in G2, phosphorylation of Cdk1 on threonine 161 via CAK (Cdk-activating
complex) maximizes the kinase activity of Cdk1 [171,197,198], which allows for
phosphorylation of its target proteins and induction of mitosis (see Figure 1.5).
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Before entering mitosis, cells survey their genome to prevent transmission of any
damaged or incompletely replicated DNA to the next generation. The contribution of
Chk1 to G2 checkpoint regulation comes from cumulative data of studies investigating
the molecular mechanisms by which anticancer drugs such as 7-hydroxystaurosporine
(UCN-01) and SB-218078 abrogate the function of G2 checkpoint [199-201]. Amongst
the kinases known to phosphorylate Cdc25C on serine 216 [202,203], such as Chk1 [199201], Chk2 [156,204] and cTAK1 (Cdc25C-associated protein kinase 1) [189], Chk1
showed the highest sensitivity (lowest IC50) to the drugs, which suggests that the
disruption of G2 checkpoint by these inhibitors is mostly through the inhibition of the
kinase activity of Chk1 towards Cdc25C phosphorylation. Phosphorylation of Cdc25C on
serine 216 creates a binding site for the members of 14-3-3 family of regulatory proteins
that are highly conserved and ubiquitously expressed [203]. The complexes of Cdc25C
and 14-3-3 are sequestered in the cytoplasm; therefore, preventing Cdc25C from
activating Cdk1 through removal of inhibitory phosphorylation of the threonine 14 and
tyrosine 15 residues. Chk1 also targets Wee1 for phosphorylation and consequently
facilitates its activation [205], which as a result allows for the maintenance of the
inhibitory phosphorylation of Cdk1. Ultimately, regulation of Cdc25C and Wee1 by
Chk1 kinase during DNA damage-induced G2 checkpoint activation results in the
maintenance of the cyclin B/Cdk1 complex in its inactive state and ensures blockage of
entry into mitosis (see Figure 1.5).
Unlike G1 checkpoint in which loss of p53 leads to total checkpoint abrogation,
p53 was found to be required for the maintenance of the arrest but not essential for the
initial arrest in G2 [206]; this was found using the human colon carcinoma cell line,
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HCT116, in which p53 was inactivated by homologous recombination. However, other
reports have demonstrated that cells with mutant p53, or having homozygous deletions in
p53, tend to selectively accumulate in G2 after irradiation [207]. It appears that, as with
the G1 checkpoint, p53 provides an additional layer of safety to the DNA damageinduced G2 checkpoint, although p53-independent mechanisms might suffice to sustain
the G2 arrest. Integrating data from different studies proposes that p53 does not induce
G2 arrest directly, but several of its transcriptional targets can regulate the G2 arrest. As
one of the well-studied targets of p53, p21 directly binds and inhibits Cdk1 [208]. 14-3-3
traps the Cdk1 in the cytoplasm where it is unable to induce entry into mitosis, and
Gadd45 binds to Cdk1 and dissociates the cyclin B subunit [208] (see Figure 1.5).
Therefore, the mechanism by which p53 contributes to the G2 checkpoint involves
repression of the cyclin B/Cdk1 complex which is essential for mitotic entry.
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Figure 1.5 Activation of G
G2 checkpoint following DNA damage.
Activated ATM and ATR phosphorylate and activate Chk
Chk2 and Chk1,
Chk respectively.
Subsequently, Chk1 or Chk
Chk2 phosphorylates Cdc25C on serine 216,, resulting in its
binding to 14-3-3 proteins and its cytoplasmic sequestration
sequestration.. Ultimately, this
relocalization of Cdc25C
C prevents the phosphatase from removing inhibitory phosphates
from Cdk1. Cdk1 remains inactive
inactive, preventing cells from entering mitosis.
mitosis ATM and
ATR, as well as Chk1 and Chk
Chk2, also phosphorylate and activate p53. This contributes to
its transcriptionall activation and expression of pp21, 14-3-3 and Gadd45
45, which can bind
and directly inhibit cyclin B
B/Cdk1 activity, sequester Cdk1 to the cytoplasm,
cytoplasm and prevent
its association with cyclin B
B, respectively. These p53-dependent
dependent events contribute to the
maintenance of G2 arrest
arrest. P: phosphorylation.
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1.8 Cellular senescence
The ends of eukaryotic chromosomes are non-coding repetitive DNA sequences
(TTAGGG), which resemble DNA breaks and therefore need to be shielded [209]. Cells
have attained this adjustment by masking the ends with a specialized protein complex,
referred to as shelterin; therefore, creating nucleoprotein structures known as termed
telomeres [210]. Telomeres protect the ends from degradation, constitutive exposure to
inappropriate action of DNA damage checkpoints, including recombination, repair,
fusion, and other activities that would lead to chromosomal instability [211]. In normal
cells undergoing continuous division, telomeres shorten in each round of replication,
creating the basis for a permanent cell cycle arrest, known as replicative senescence [212218]. Telomeres that become eroded or uncapped and dysfunctional elicit widespread
checkpoint responses, which initiate and maintain the long-term irreversible arrest of
senescence [219,220]. Not only in the case of telomere erosion, but also in cells suffering
from other genomic lesions delivered by oncogenic activities [221] and DNA damage
[222], reinforcement of senescence is a safeguard against unregulated proliferation and
neoplastic transformations.
Senescence is indeed an alternative to self-destructive mechanisms, yet more
advantageous to cells because it is less destructive; it is fully distinct from quiescence or
terminal differentiation [223]. Although gene expression widely changes in senescent
cells, these changes are not to the extent to be specific enough to be assigned as markers
shared by all cells undergoing senescence. Given that such a common feature has not
been characterized to be defined as a senescent cell, cells must encompass several other
distinct features. Generally, permanently arrested senescent cells display a characteristic
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enlarged, flattened morphology [212], they express senescence-associated β-galactosidase
(SA-β-Gal) [224], and they develop a secretory phenotype (senescence-associated
secretory phenotype; SASP) [225]. Active signaling pathways inside senescent cells
induce changes in the structure of chromatin and cause formation of distinct chromatin
structures called senescence-associated heterochromatin foci (SAHF) [226]. Formation of
SAHFs proceeds through hetero-chromatinization and permanent repression of E2F
target genes via activation of the tumor suppressor Rb [226]. These features are shared
not only by cells undergoing replicative senescence, but also found in prematurely aging
cells that are exposed to stressors such as DNA damaging insults. In such premature
senescent cells, persistent DNA damage signals create another specialized nuclear
structure, termed DNA segments with chromatin alterations reinforcing senescence
(DNA-SCARS) [227]. These foci accumulate some activated checkpoint signaling
proteins, including Chk2 and p53 [227].
Both telomere shortening and DNA damage-induced cellular senescence are
stimulated by a common mechanism, the DDR pathway, and are efficient when p53 and
Rb pathways are functional [228]. Short, dysfunctional telomeres and accumulated breaks
in the DNA trigger the activation of ATM/Chk2 and ATR/Chk1 kinases, causing an
arrest in the G1 phase of the cell cycle that can be maintained by activation of the tumor
suppressor p53 and its transcriptional target, Cdk inhibitor p21. By activation of DDR,
different repair associated proteins relocate to the sites of damage where the broken ends
are surrounded by other phospho-activated substrates, such as the histone variant γH2AX. The build-up of repair proteins and the γ-H2AX proteins assemble γ-H2AX foci
structures, which are considered functional biomarkers of most, if not all, types of

27

senescence [80,229-232]. Telomere dysfunction-induced foci (TIF), which are observed
in uncapped dysfunctional telomeres, are also associated with almost the same proteins
involved in the formation of γ-H2AX foci [233]. Even though dysfunctional telomeres
trigger a similar response and share many of the same proteins as DNA damage-induced
breaks, repair mechanisms like non-homologous end joining (NHEJ) are able to join any
two dysfunctional chromosomal ends and lead to chromosomal fusions by recombination
[234]. Constantly active DNA damage mechanisms can, independent of p53 and p21,
cause an induction of Rb/E2F signaling pathway. This regulation is mediated through
members of another class of CKIs, INK4A/ARF. The cyclin dependent kinase inhibitor
2A (CDKN2A, INK4A, p16) is a potent tumor suppressor protein which is mostly known
for its inhibitory activity on Cdk4 [135] and Cdk6 [136] in early G1, by competing with
cyclin D to bind to these Cdks. Upon mitogenic stimulation, D-type cyclins bind and
activate Cdk4 and Cdk6 kinases present in the nucleus. Rb is hyper-phosphorylated by
the resultant cyclin D/Cdk4/6 complexes, thereby liberating the active E2F [137139,141]. Active E2F proteins mediate transcriptional activation of a variety of proteins
required for G1 to S progression, including cyclin E [235] and cyclin A [226] proteins.
Increased levels of cyclin E/Cdk2 and presumably cyclin A/Cdk2 complex can continue
phosphorylation of Rb and creating the hyper-phosphorylated Rb which further releases
active E2F molecules [140,236]. Inhibition of Rb phosphorylation, through inhibition of
the activity of Cdk4 and Cdk6 with inhibitors such as p16, in turn leads to inhibition of
cell progression from G1 to S phase [236] (see Figure 1.6).
Although at first glance p53/p21 and Rb/p16 pathways may seem to be two
distinct parallel pathways, they are tightly linked. The p21 protein can impose p53-
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mediated activation of Rb by inhibition of cyclin D/Cdk4/6 and cyclin E/Cdk2 complexes
[146]. However, p21 cannot be considered the sole regulator of Rb, since MEF (mouse
embryonic fibroblast) cells can undergo senescence, regardless of their p21 status [237].
Not only p21, but its transcriptional regulator p53 can also contribute to the regulation of
Rb/p16 pathway. Transcriptional activation of p53 promotes expression of the helix-loophelix transcriptional regulator protein Id1 (inhibitor of DNA binding 1), a well-known
transcriptional repressor of p16, to negatively regulate p16 expression [238-240].
Reciprocally, p16 regulates p53 expression by both decreasing its transcriptional
expression and increasing its Mdm2 mediated degradation [241] (see Figure 1.6).
Although the existence of crosstalk between two paradigmatic p53/p21 and
Rb/p16 pathways in induction of senescence cannot be discarded, it appears that distinct
stimuli converge on one another to establish and maintain the senescence state. In
situations like oncogene-induced senescence, Ras onco-protein [221] or its downstream
effectors such as Raf [242] may cause activation of both p53 and p16 [221], but it is p16
that appears to play the major role. The prominent contribution of p16 in this type of
senescence was developed under the studies showing that its deficiency is sufficient to
delay appearance of senescence in cells [243]. Additionally, using fibroblasts expressing
a range of p16 proteins levels, only cells with higher p16 levels respond to overexpression of Ras by inducing premature senescence [244]. In senescence states induced
by short, dysfunctional telomeres [245] and DNA damage [246,247], Rb through the p16
pathway is involved in senescence stimulation. However, later studies provide evidence
that inactivation of p53 also suffices to prevent or, at least, significantly delay replicative
senescence that occurs by dysfunctional telomeres [248,249] or premature senescence
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triggered by DNA damage [250,251]. Although inactivation of either Rb or p53 is
sufficient to allow the cells to continue growth, which pathway, p53/p21/Rb or p16/Rb,
do cells prefer to establish or maintain the prolonged irreversible arrest? Analysis of
single cells undergoing replicative- or DNA damage-induced senescence has provided
more evidence for the notion that increased levels and activation of p53 and p21 coincide
with the onset of senescence. However, gradual increase in p16 levels during this period
provides the cells a “back-up” mechanism to remain senescent [246,252]. Collectively,
cellular senescence is a coordinated program accomplished by cells to cease division, in
response to various types of stresses. Upon entering senescence, cells undergo
physiological and morphological changes that reflect a shift in their gene expression.
Amongst the signaling pathways triggered by this phenomenon, p53/p21 and p16
pathways have drawn more attention. While in response to different stimuli, one or
another plays a more dominant role, senescence induced by short, dysfunctional
telomeres (replicative senescence) or DNA damage tends to immediately activate p53
and p21 and raises their levels. During this period, p53 imposes its negative regulation on
p16 to reduce its overall levels. However, p16 levels gradually increase and negatively
modulate p53 to maintain the state of senescence. Therefore, orderly activation of
p53/p21/Rb pathway followed by the p16/Rb pathway coordinates the progression of
senescence (see Figure 1.6).
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Figure 1.6 Activation of senescence by DNA damage and telomere uncapping.
uncapping
Telomere uncapping and lesions in the DNA induce a DDR, mediated by ATM/Chk2
ATM
and
ATR/Chk1 to stabilize and activate pp53. Expression of p21, induced by p53,
p
inhibits
cyclin/Cdk
Cdk complexes thereb
thereby activating Rb. Rb sequesters E2F
F and inhibits the
transcription of E2F
F target genes that are required for S phase entry
entry.. p53 can activate
senescence, independently of Rb
Rb. Activation of Rb can also be achieved
ieved by expression of
p16. P: phosphorylation..
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1.9 Cdk activators
Progression of the cell cycle and transition from one phase to another occur by the
balance between active and inactive forms of the Cdks. To become functional, activation
of Cdks must be tightly coupled by a combination of mechanisms, the foremost being
their binding to activating partners, the cyclins. Dynamic regulation of cyclins through
their periodic synthesis and destruction provides a spatio-temporal control over activation
of Cdks. Particular combinations of cyclin and Cdk proteins are responsible for specific
events during each step of the cell cycle. While the cyclin D/Cdk4/6 complex drives the
progression through the G1 phase [253], cyclin E/Cdk2 facilitates the transition from G1
to S [254,255]. Subsequently, increased expression of cyclin A, in association with Cdk2
and later with Cdk1, provides progression through the S phase and the G2/M transition,
respectively [256]. By transition to G2 phase, newly synthesized cyclin B proteins, in
association with Cdk1, contribute to progression through G2 and entry into the next
phase, mitosis [257]. At the end of each round, loss of Cdk activity returns the cell to the
start point. It appears that cyclins do not simply activate their Cdk partners, but often
target them to specific sub-cellular locations to convey distinct substrate specificity to
Cdks [258]. Therefore, the availability of substrates and their specificity, imparted by
cyclins, make substrates accessible to Cdks and ensure the sequential order of cell cycle
events.
Cyclin/Cdk regulation of cell cycle progression is closely linked to other cell
cycle-related events, including checkpoint activation, senescence, and apoptosis.
Although the roles of Cdks in cell cycle have been extensively studied, the precise
contribution of Cdks to these phenomena has not been fully illuminated. Whether their
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contribution is through their binding to the classical activating partners and the wellestablished substrates, or requires the help of other binding partners and changes in their
substrate specificity, has remained elusive.
Although cyclins are strictly essential for functionality of Cdks during progression
of cell cycle, they are not sole activators of Cdks. The non-cyclin class of Cdk activators,
or atypical Cdk activators, can stimulate the activity of Cdks. Cdks activated by these
proteins share distinct characteristics; they have altered substrate specificity [259,260],
are less susceptible to inhibition by CKIs such as p21, p27 and p16 [261,262], and do not
require proper phosphorylation status at their inhibitory or activating residues [263].
Amongst these non-cyclin Cdk activators, a newly discovered family termed
speedy/RINGO (rapid inducer of G2/M progression in oocytes) can activate Cdk1 and
Cdk2 but not Cdk4 or Cdk6, and possess all the typical characteristics of non-cyclin Cdk
activators.
1.9.1 Speedy/RINGO Family
The speedy/RINGO family was initially discovered by identification of Xenopus
speedy (Spy1). In a screen searching for novel Xenopus gene products that act at G2/M
transition, a clone expressing Spy1 partially rescued the sensitivity of rad1 deficient
Saccharomyces pombe strain, K1, to UV as well as gamma irradiation [264].
Investigating its function revealed its physical interaction with Cdk2 [264]. In addition to
Cdk2 activation, through the activation of MAPK (mitogen-activated protein kinase) and
MPF (M phase/maturation promoting factor, the cyclin B/Cdk1 complex), Spy1 was able
to induce rapid maturation of Xenopus oocytes [264]. Independent of Spy1 discovery,
Xenopus RINGO (X-RINGO) was isolated in a screen to identify proteins involved in
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G2/M transition during the meiotic maturation of Xenopus oocytes [265]. The cDNA
encoding RINGO could induce meiotic maturation in G2-arrested oocytes through the
activation of MPF [265]. In addition, removal of the endogenous RINGO mRNAs
inhibited maturation of oocytes by progesterone, indicating its requirement for this
process [265]. The finding that both speedy and RINGO proteins were able to induce
oocyte maturation was further supported by later studies revealing that elevated levels of
speedy accelerated meiotic maturation of porcine oocytes [266] and induced germinal
vesicle breakdown (GVBD) in mouse oocytes [267], while its ablation in rat deregulated
spermatogenesis [268,269].
Homologs of speedy/RINGO have been identified in a wide range of vertebrates,
from the most primitive branching clades of chordates (Ciona intestinalis [270] and
Cephalochordata [271]) to those at the very top of the hierarchy, but not in invertebrates.
In mammals, six homologs of speedy/RINGO have been characterized (see Table 1.1).
The two isoforms of speedy/RINGO A, which differ in their C-terminal regions with A2
being 27 amino acids longer, are the splice variants of the same gene. It appears that
among all the speedy/RINGO family members, speedy/RINGO A is conserved in all
chordates. For instance, human and mouse speedy/RINGO A are more than 75% similar
[271]. Speedy/RINGO A is highly expressed in brain and testis, and can also be found in
kidneys, lungs, spleen, and ovaries [270]. The oscillatory expression of this protein
during the cell cycle, similar to cyclins, is controlled at the levels of transcription and
translation [272]. Similar to cyclin A2, mRNA of speedy/RINGO A protein was found at
the peak of its expression in M phase and very low at late G1 [219]. The protein,
however, was accumulated during G1 stage, and with only detectable levels in other
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phases of the cell cycle [272]. Upon exiting G1 phase, speedy/RINGO A is targeted for
degradation by the SCFSkp2 (Skp, cullin, F-box containing complex/S-phase kinaseassociated protein 2) complex [272].
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Name

Species

Cdk partner

Reference

Speedy (Spy1)
RINGO

Xenopus laevis

Cdk1/Cdk2

[264,265]

Speedy/RINGO A1
(SpyA1/Spy1)

Homo sapiens/
Mus musculus

Cdk2

Speedy/RINGO A2
(SpyA2)

Homo sapiens/
Mus musculus

Cdk1/Cdk2

Speedy/RINGO B

Mus musculus

Cdk1

Speedy/RINGO C

Homo sapiens

Cdk1/Cdk2

Speedy/RINGO D

Mus musculus

-

Speedy/RINGO E

Homo sapiens

Cdk1/Cdk2/Cdk5

Table 1.1 Speedy/RINGO family members.
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[270,273]

[270]

[270,272]

[270,272]

[270]

[272]

1.9.2 Speedy/RINGO structure
All speedy/RINGO family members exhibit a substantial amino acid sequence
identity in a contiguous stretch of ~140 amino acids located in the central region, termed
the speedy/RINGO box (S/R box) [270,273] (see Figure 1.7). All mammalian
speedy/RINGO proteins were found to be 51-67% identical to Xenopus speedy/RINGO
in a stretch of 79 residues [274]. The S/R box is responsible for the direct binding of the
speedy/RINGO proteins to Cdks and their subsequent activation [270]. Although the S/R
box has no obvious sequence-based homology with the cyclin box, it is predicted to have
an α-helical secondary structure [274]. It might fold into a conformation very similar to
that of the cyclin box; structural studies should unravel this possibility. The intact
sequence of S/R box appears to be a necessity for speedy/RINGO binding to Cdks and its
functionality during GVBD [273]. While deletion of amino acids flanking the S/R box
did not abolish the ability of Xenopus speedy/RINGO to induce oocyte maturation [273],
truncated Xenopus speedy/RINGO containing only the S/R box (residues 60-204) could
induce oocyte maturation [270,272]. Mutational analysis of conserved and polar residues
throughout the S/R box revealed that most of the residues within the S/R box were
necessary for Cdk binding; aspartic acid 90, methionine 103, tyrosine 107, and
phenylalanine 108 were of importance [270]. When assayed to measure the induced Cdk2
activity, only full length speedy/RINGO A2 and a mutant lacking the N-terminal region
(residues 1-59) activated Cdk2 efficiently, indicating that the N-terminus of Spy1 is
dispensable for Cdk2 activation [270]. Although truncated S/R box on its own can bind to
Cdk2, it could not induce Cdk2 activation [270], suggesting the requirement of other
regions for Spy1 function. Residues in the C-terminus (205-311) are also implicated in
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the function of speedy/RINGO proteins, as deletion of this region abolishes
speedy/RINGO A2 activation of Cdk2, but not its binding [270] (see Figure 1.7).
Although the N-terminus of Spy1 is dispensable for Cdk activation, it was found
to affect protein abundance in transfected cells [270]. Deletion of amino acids 1-59
clearly increased the abundance of speedy/RINGO A2 in transfected HEK-293 cells,
revealing the negative effect of this region on the stability of protein [270]. Consistently,
N-terminal tagging of Spy1, for instance fusion to GFP or 6xMyc, could improve
accumulation of ectopically expressed Spy1 [272]. Research seeking the responsible E3
ligase for degradation of Spy1 protein further clarified the essentiality of N-terminal
region in degradation of the protein [275]. Using a panel of Spy1 deletion mutants, only
the mutant lacking the first 57 amino acid residues was stabilized in cells synchronized at
G2/M transition [275]; this suggested the possibility of the existence of a degradation
signal in this region. Phosphorylation status of three polar residues, threonine 15, serine
22, and threonine 33, in N-terminus of Spy1 was found as the key signal in regulation of
Spy1 turnover at G2/M transition [275] (see Figure 1.7). In addition to these sites,
speedy/RINGO A2 was found hyper-phosphorylated in mitosis at threonine 10 and a
sequence of serine residues located at the C-terminus (residues 242-249); however, there
is a need for further investigation to provide a better understanding of their role [272]
(see Figure 1.7).
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Figure 1.7 Speedy/RINGO A structure.
The speedy/RINGO box (residues 60 to 204) in central region of speedy/RINGO proteins
mediates its interaction with Cdk kinases. A potential nuclear export signal (NES) is
predicted between amino acids 121 and 129 within the S/R box. The N-terminal flanking
region contains a degradation signal, while the C-terminal region is thought to be
essential for activation of Cdks by speedy/RINGO proteins.
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1.9.3 Interacting partners of speedy/RINGO proteins
Physical interaction of speedy/RINGO proteins with Cdks was first revealed by
the finding that Xenopus speedy could prematurely activate Cdk2 [264]. Although a
direct interaction between Xenopus speedy and Cdk2 was not tested, Xenopus speedy was
immune-precipitated with Cdk2, suggesting their association in a complex [264].
Xenopus RINGO, although competed with cyclin B to interact with Cdk1, was found to
preferentially bind to free Cdk1 molecules [265]. Human speedy, Spy1, was initially
presented as a Cdk2 activator, which could enhance cell proliferation [273]. Direct
binding of Spy1 to Cdk1 and Cdk2 was later evaluated through in vitro studies [270].
Spy1 was shown to directly bind to both Cdk1 and 2 and induced their histone H1 kinase
activity [270].
The direct interaction between Spy1 and p27 was demonstrated using a yeast two
hybrid screen where Spy1 was used as bait to identify its interacting partners [276]. This
interaction involves the Cdk binding region of p27 (residues 53 to 93), between amino
acid 43 to 128, rather than the cyclin binding region [277]. Although independent of p27,
Spy1 can associate with Cdk2, the presence of p27 stimulates this interaction, suggesting
the formation of Cdk2/Spy1/p27 complex, which results in p27 degradation and
activation of Cdk2 [276].
Targeted degradation of Spy1 by the E3 ligase Nedd4 (neuronal precursor cellexpressed developmentally down-regulated 4) creates another binding partner for the Cdk
regulator Spy1 [275]. Previously, it was demonstrated that Spy1 is ubiquitinated and
degraded during G2/M phase transition by Nedd4 ligase, which requires phosphorylation
of the protein on N-terminal residues [275]. Degradation of Spy1 by the ubiquitin ligase
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SCF, however, requires direct interaction of Spy1 with the F-box protein Skp2 [272].
Spy1 was found inversely expressed with Skp2 levels throughout the cell cycle; it also
immune-precipitated with its F-box protein, supporting the binding of Spy1 to Skp2 to
mediate its ubiquitination and degradation [272].
1.9.4 Speedy/RINGO activation of Cdks
Activation of Cdks by members of speedy/RINGO family shows significant
mechanismal differences in comparison to their classical binding activators. Activation of
Cdks by speedy/RINGO protein is independent of the threonine phosphorylation of the
activating loop (T-loop) by CAK, which is essential for full Cdk activation by cyclins
[278]. Although the inhibitory phosphorylation of threonine 14 and tyrosine 15 residues
by Myt1 and Wee1 kinases reduces the kinase activity of Cdks induced by
speedy/RINGO proteins, speedy/RINGO/Cdk complexes are more resistant to this kind
of inhibition than cyclin/Cdk complexes [278]. Moreover, while in complex with
speedy/RINGO proteins, Cdks are less susceptible to inhibition by Cdk inhibitors, p21
and p27 [273,278]. Unlike cyclins, speedy/RINGO proteins bound to Cdks are found to
be poor substrates for the activating and inhibitory kinases of Cdks, CAK and Myt1,
respectively [278,279]. Differential regulation of Cdks by speedy/RINGO proteins is not
limited to their activation, but also alters their substrate specificity [279]. Similar to
cyclins, speedy/RINGO proteins may uniquely interact with their target substrates, when
available, and make them accessible to their interacting Cdk partner.
1.9.5 Spy1 regulation of the cell cycle
The human speedy/RINGO A (Spy1) was uncovered during a search of an EST
database for gene products bearing sequence homology with Xenopus speedy/RINGO,
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with overall similarity of ~40% or higher in the central region [273]. Similar to its
Xenopus counterpart, although slower, human Spy1 induced GVBD, and raised the
possibility of activation of cyclin B/Cdk1 complex [273]. The mRNAs encoding Spy1
protein, however, were detected only during the G1/S stage of the cell cycle in human
cells and the protein was located in the nucleus, which suggested the possibility of Spy1
interaction with Cdk2 [273]. Over-expression of Spy1 resulted in enhanced rate of
replication and division of cells. Cells with elevated Spy1 expression proliferated faster,
incorporated higher levels of BrdU, and displayed increased mitochondrial activity and
phosphorylation of histone H3 [273]. Initially, the proliferative effect of Spy1 was linked
to its interaction with Cdk2 and direct activation of the kinase, since the inhibition of
Cdk2 activity, using the Cdk inhibitor Olomoucine, or over-expression of a catalytically
inactive Cdk2, abolished the ability of Spy1 to stimulate proliferation [273]. However,
discovering novel binding partners for Spy1 in a yeast two-hybrid screen, p27 being one
of them, changed the view of how Spy1 stimulates cell proliferation [276]. Disruption of
Cdk2/p27 interaction with the presence of Spy1 has two major outcomes. First, Spy1
binds to p27 and inhibits p27 to enforce its effects on Cdk2; therefore, allowing for
increased Cdk2 kinase activity [276]. Second, activated Cdk2, by phosphorylating p27 on
threonine 187, targets the protein for ubiquitin-dependent degradation by SCFSkp2
complex, which further induces activation of Cdk2 and promoting G1/S transition [277].
Applying cell lines deprived of endogenous p27, p27 was found to be essential for Spy1
to render its proliferation effect [277]. However, in such a system Spy1 is still bound to
Cdk2, presumably to accomplish its other Cdk-dependent functions, such as those in
checkpoint activation, apoptosis or others.
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1.9.6 Spy1 and the DNA damage response
The initial observation that Spy1 expression conferred a partial resistance to
radiation in a rad1 deficient yeast strain suggested the possible involvement of this
protein in DDR pathway [264]. In parallel with this data, expression of Spy1 in
mammalian cells also enhanced survival under different genotoxic conditions [280].
Further investigations demonstrated that in response to UV irradiation, Spy1 effect on
cell survival is mediated by suppression apoptosis [281]. When irradiated, cells stably
over-expressing Spy1 had lower percentage of sub-G1 DNA content and were less
stained with Annexin V [281]. Unlike the wild-type protein, the S/R box mutated Spy1
failed to suppress apoptosis when faced with UV irradiation [281], suggesting that Spy1
must interact with Cdk2 in order to suppress apoptosis. To suppress apoptosis, Spy1 was
found to block cleavage of Caspase-3 (cysteine-aspartic proteases 3) and accumulation of
its cleaved fragments [281]. Later work has found that not only its interaction with Cdk2,
but also the presence of functional p53 and p21 proteins are required for anti-apoptotic
function of Spy1, as Spy1 over-expressing cells lacking either of these tumor suppressor
proteins showed no suppression of apoptosis following UV irradiation [282]. In addition,
up-regulation of Spy1 suppresses the activation of checkpoint signaling pathway by
preventing the phosphorylation and activation of signaling molecules, such as Chk1,
RPA32, and H2AX [281]. Over-expression of Spy1 not only inhibits activation of
checkpoint proteins, it overrides the checkpoints as well, as it was accompanied by
increasing levels of phospho-histone H3 [281]. It appears that these effects are mediated
through the activation of Cdk2, as mutation of S/R box region of Spy1, which is known
to be essential for the interaction with Cdk2, abolishes the regulation of checkpoint
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signaling by Spy1 [281]. Together, these results indicate a specific role for the regulation
of Spy1 in modulating the DDR, in both the checkpoint activation and apoptosis.
Although unregulated expression of Spy1 disrupts the checkpoint signaling, ablation of
the protein causes proliferation defects [282]. Collectively, proper regulation of Spy1
appears to be a necessity for cells when challenged with genotoxic stresses to keep the
balance between checkpoint activation and proliferation.
1.10 Specific aims
This research aims to clarify the regulation of Spy1 protein during checkpoint
activation induced by UV irradiation, as well as to investigate the possible effects of
Spy1 on cellular responses such as cellular senescence. To determine whether, in
response to DNA damage, tight regulation of Spy1 must be achieved, or whether its
misregulation contributes to DDR pathway control, the following aims were pursued:

1. To elucidate the regulation of Spy1 during DNA damage and the molecular mechanism
by which this regulation occurs by the checkpoint signaling molecules (addressed in
chapter 2).
2. To examine the Spy1 regulation of cellular senescence induced by DNA damage or
telomere shortening and how this regulation is achieved (addressed in chapter 3).
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Chapter 2: Degradation of Spy1 Protein Following UV Irradiation Is
Dependent on the DNA Damage Response Pathway
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2.1 Introduction
Maintenance of DNA integrity is crucial for the viability of an organism. In
response to genotoxic stress [1], critically shortened or dysfunctional telomere structures
[2,3], proto-oncogene activation, and replicative stress [4], cells trigger a cascade of
events leading either to appropriate DNA repair, cellular senescence, or apoptosis in the
case of overwhelming damage. Cell responses to DNA damage are coordinated by two
distinct kinase-signaling cascades, which possess some overlapping functions. DNA
double-strand breaks (DSBs) lead to the activation of the kinase ATM (ataxia
telangiectasia mutated) [5], followed by phosphorylation and activation of the transducer
kinase, Chk2 [6]. Similarly, single-stranded DNA leads to the activation of the kinase
ATR (ataxia telangiectasia and Rad3-related) [7,8], followed by phosphorylation and
activation of the transducer kinase, Chk1 [7,8]. Primary and secondary effectors of these
signaling kinases include members of the Cdc25 (cell division cycle 25) family of protein
phosphatases [9-11] and the important tumor suppressor protein, p53 [12]. ATM and
ATR can phosphorylate p53 directly on serine 15 [13] and Chk1 and Chk2 can
phosphorylate p53 on serine 20 [14]. Phosphorylation of these two key residues is
required for p53 activation [15]. Moreover, these phosphorylation events must precede
the phosphorylation on other residues, such as threonine 18 [16,17], which stabilize the
protein by preventing its binding to the negative regulator, Mdm2 (mouse double minute
2) [18,19]. As a transcription factor, p53 transactivates or transrepresses genes initiating
cell cycle arrest, repair, or apoptosis. One example is the transcriptional activation of the
cyclin-dependent kinase inhibitor (CKI) p21, an event which leads to persistent inhibition
of the G1/S Cdk, Cdk2, and maintenance of the DNA damage-activated G1 checkpoint
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[20,21]. Regulation of Cdk activity represents a pivotal event in executing decisions to
arrest, repair DNA, re-enter the cell cycle or activate the processes of apoptosis in
response to DNA damage [22]. While processes such as these are well established, the
detailed mechanisms by which Cdks contribute to these essential cellular events are still
unclear. Furthermore, while a great deal is known about the biochemical and molecular
regulation of the Cdks, recent data show ‘atypical’ mechanisms to regulate these kinases
that are currently understudied [23]. Revealing novel mechanisms regulating the activity
of these kinases will clarify how cells respond to DNA damage.
Members of the speedy/RINGO (rapid inducer of G2/M progression in oocytes)
family of proteins are atypical Cdk activators, with no sequence-based homology to the
classical cyclins that preferentially bind and activate both Cdk1 and Cdk2 [24,25].
Xenopus speedy was initially isolated in a screen searching for genes that could confer
resistance to a rad1-deficient Schizosaccharomyces pombe strain in response to UV and
gamma irradiation [24]. Independently, in an expression-cloning screen to identify genes
involved in induction of G2/M transition in Xenopus oocytes, Xenopus RINGO was
discovered [25].
The human ortholog, speedy A1 (Spy1, SpyA1), is known to play a role in cell
proliferation [26]. In addition to Cdk activation, over-expression and knock-down studies
have revealed novel regulatory roles for Spy1. Spy1 is capable of overriding cell cycle
checkpoint activation and to inhibit apoptosis in the face of DNA damage [27].
Specifically, elevated levels of Spy1 in cells irradiated with UV impair ATR checkpoint
signaling [27]. This is accomplished by inhibition of Chk1 activation and decreased
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activation of proteins involved in the checkpoint response such as phospho-H2A.X and
RPA32 (replication protein A, subunit 32) [27].
Hence, previous data supports the hypothesis that Spy1 protein levels must be
tightly regulated to avoid defects in DNA damage-mediated checkpoints. In this study,
we report for the first time, that endogenous levels of Spy1 protein are inversely
regulated with that of the tumor suppressor p53 during the cellular response to UV
irradiation. We demonstrate that following DNA damage, Spy1 protein levels decrease
and this degradation is sensitive to inhibition of the proteasomal machinery. Furthermore,
we show that Spy1 protein degradation following UV exposure occurs in a manner that is
dependent on Chk2 and p53.
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2.2 Material and methods
Cell culture
Human embryonic kidney cells, HEK-293 (CRL-1573; ATCC) were maintained
in Dulbecco’s Modified Eagle’s Medium (DMEM; D5796; Sigma) supplemented with
10% fetal bovine serum (FBS; F1051; Sigma). The human osteosarcoma cells, U-2OS
and Saos-2 (kindly provided by Dr. J. Hudson, University of Windsor) were cultured in
McCoy’s 5A 1X medium (10-050-CV; Cellgro-Mediatech) with 10% FBS. NIH/3T3
cells (kindly provided by Dr. J. Hudson, University of Windsor) were cultured in DMEM
supplemented with 10% calf serum (C8056; Sigma). Human colon carcinoma cell lines,
HCT116 p21+/+, p21-/-, p53-/-, and Chk2-/- (generous gifts from Dr. B. Vogelstein,
Johns Hopkins School of Medicine) were maintained in McCoy’s 5A media,
supplemented

with

10%

FBS.

All

cells

were

supplemented

with

1%

penicillin/streptomycin and were maintained in an atmosphere of 5% CO2 at 37˚C.
Plasmids
Myc-pCS3 [28] and Myc-Spy1A-pCS3 [26] vectors were described previously.
Flag-Chk1-pcDNA4 and Flag-Chk2-pcDNA3 constructs were generously provided by
Dr. Junjie Chen (University of Texas). Flag-p53-pcDNA3 construct was purchased from
Addgene (#10838).
Transfections
Plasmids were transiently transfected using jetPRIME transfection reagent
(CA89129-922; VWR). In brief, a total of 4 µg DNA was diluted in 200 µl of jetPRIME
buffer. After vortexing the mix, 4 µl jetPRIME was added and vortexed. Reaction was
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incubated for 10 minutes at room temperature. The transfection mix was added drop-wise
into the medium. Cells were incubated at 37˚C for at least 24 hours.
UV irradiation
Exponentially growing cells were washed once with PBS and then subjected to
UVC. UVC irradiation was performed using a GS Gene Linker (Bio-Rad). Fresh medium
was added to the culture dishes immediately after irradiation.
Compounds and antibodies
The following antibodies were used: p53 (DO-1; sc-126; Santa Cruz), pS15-p53
(9284; Cell Signaling), c-Myc (9E10; sc-40; Santa Cruz), FLAG (F1804 and F7425;
Sigma), and actin (MAB1501R; Chemicon). Affinity purification of rabbit antisera to
Spy1 has been previously described [26]. Secondary antibodies used were HRPconjugated anti-mouse (A9917; Sigma) and anti-rabbit (A0545: Sigma) IgG.
The following compounds at the specified concentrations were used: MG132
(C2211; Sigma): 10-25 µM, cycloheximide (C7698; Sigma): 25 µM, UCN-01 (U6508;
Sigma): 100 nM, and Chk2 inhibitor II (C3742, Sigma): 1 µM.
Immuno-blotting
Samples were lysed with 0.1% NP-40 buffer supplemented with Leupeptin (5
µg/ml), Aprotinin (5 µg/ml), PMSF (100 µg/ml), and Sodium orthovanadate (1mM).
Samples were analyzed by 7.5-12.5% SDS-PAGE then transferred to a PVDF membrane.
Primary and secondary antibodies were applied and incubated at different dilutions.
Proteins were detected via treatment with Perkin-Elmer Enhanced Chemiluminescence
reagent and quantified using FlourChem HD2 software (AlphaInnotech; Perkin Elmer).
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Real-time PCR
Total RNA was isolated using a commercial mini-preparation kit (RNeasy™,
Qiagen). First-strand cDNA was synthesized using SuperScript™ II Reverse
Transcriptase (18064; Invitrogen). Relative quantities of mRNA expression were
analyzed using real-time PCR (ABI 7300 Sequence Detection System, Applied
Biosystems). In this study, SPDYA and 18SRNA levels were quantified by Taqman
expression assays Hs00736925_m1 and Hs99999901_s1, respectively.
Statistical analysis
Student’s t test was employed using Statistica software. All results are expressed as mean
± SEM from at least three individual experiments and differences were considered
significant at p values of ≤ 0.05.
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2.3 Results
2.3.1 Spy1 protein levels are tightly regulated during the DNA damage response.
To explore the regulation of endogenous Spy1 protein in response to DNA
damage, U-2 OS cells were exposed to 30 or 50 J/m2 of UV. Cells were collected at the
times indicated, lysed and immuno-blotted for Spy1 and p53, with actin as the loading
control. We observed that Spy1 levels decreased in UV-irradiated cells (Figure 2.1A;
upper panels). By signal quantification and normalization against the endogenous control
we could also determine reciprocal expression between Spy1 and p53 (Figure 2.1A;
lower panels). Consistent with the endogenous protein, ectopically expressed Spy1
protein was effectively degraded in response to DNA damage in multiple cell lines (U-2
OS, HCT116 parental, NIH/3T3, and HCT116 p21-/-) (Figure 2.1B). In each of these
cases, Spy1 protein levels were quantified and results showed reduction in the Spy1
abundance following UV irradiation. However, statistical analysis of the results
demonstrated that down-regulation of Spy1 protein in both HCT116 parental and p21-/was not significant. These results support the hypothesis that Spy1 levels are tightly
regulated during the DNA damage response.
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A.

B.
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Figure 2.1 Spy1 protein levels are down-regulated following UV irradiation.
A. Endogenous levels of Spy1 protein following exposure of U-2 OS cells to UV
irradiation. Cells were irradiated with 30 or 50 J/m2 of UV and harvested for Western blot
analysis at the indicated time points, in hours (h). Endogenous Spy1, p53 and actin levels
were monitored by immuno-blotting. Densitometry analysis of one representative
experiment (lower panels) was conducted comparing Spy1 and p53 protein levels
normalized to actin. N>3. B. Exogenous levels of Spy1 protein following exposure of U2 OS, NIH/3T3, HCT116 parental or p21-/- cells to UV irradiation. Cells transfected with
Myc-pCS3, or Myc-Spy1-pCS3 plasmids were untreated (left lanes) or irradiated with 50
J/m2 of UV (right lanes) and harvested for Western blot analysis after 24 hours. Spy1 and
actin levels were monitored by immuno-blotting. Densitometry of N=3 (right panel) is
shown as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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2.3.2 Reduced levels of Spy1 following UV irradiation is regulated at the protein
stability level.
We then tested whether reduced levels of Spy1 protein are occurring in a
proteasome-dependent manner. To investigate the degradation of endogenous Spy1
protein, U-2 OS cells exposed to either 50 J/m2 UV or mock irradiated for 12 hours were
treated with the vehicle control (DMSO), 25 µg/ml cycloheximide (CHX) to block de
novo protein synthesis, or cycloheximide with the 26S proteasome inhibitor MG132 (25
µM) for an additional 6 hours (Figure 2.2A). In the presence of cycloheximide,
endogenous Spy1 protein levels were significantly depleted following UV treatment
(Figure 2.2A), supporting that Spy1 is regulated at the protein stability level. In the
presence of MG132, Spy1 levels were significantly stabilized overall (Figure 2.2A);
however, UV treatment continued to significantly reduce Spy1 levels, suggesting that a
proteasome-independent mechanism may play a role in Spy1 degradation following UV
damage. Whether proteasome was fully inhibited following MG132 treatment was not
tested in this experiment; looking at the levels of other proteins known to be degraded by
the proteasome following UV irradiation would have clarified this problem.
When driving Spy1 expression using a constitutive promoter, cells exposed to UV
and treated immediately after with MG132 and 2 hours later with CHX showed that Spy1
protein levels were significantly depleted, further supporting that depletion is occurring at
the post-translational level (Figure 2.2B). Interestingly however, in the presence of
MG132, ectopically over-expressed protein was not depleted following UV damage,
showing a role for proteasome-dependent degradation in the stabilization of Spy1 protein
following UV (Figure 2.2B). To investigate whether the time-dependent down-regulation
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of Spy1 can be seen at the mRNA level, mRNA from U-2 OS cells exposed to UV
irradiation was assessed by quantitative real-time PCR (Figure 2.2C). Analyzing the
results showed fluctuations in the levels of mRNA. Although mRNA levels, similar to
protein levels of Spy1, were declined at later time points following UV exposure, the
initial increase prior to the decline was not observed at the protein levels.
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Figure 2.2 Inhibition of proteasomal machinery restores the level of Spy1 protein
following UV irradiation.
A. and B. U-2OS cells were left untransfected (A) or transfected with Myc-pCS3 control
or Myc-Spy1-pCS3 (B) in the presence or absence of 50 J/m2 of UV. Cells were treated
with cycloheximide (CHX; 25 µg/ml) following DMSO or 20 µM MG132 treatment.
Cells were harvested 6 hours (A) or 14 hours (B) after CHX treatments to monitor Spy1
protein stability. The panels on the right represent quantitative analysis of three
individual experiments. Densitometry of N=3 (right panels). Values represent the mean ±
SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. C. Quantitative real-time PCR analyses of
SPDYA mRNA in UV irradiated U-2 OS cells. Histogram shows mean mRNA expression
of SPDYA gene at time points indicated following 50 J/m2 exposure. Represented data
are mean ± SEM of three individual experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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2.3.3 Activation of Chk2 initiates degradation of the Spy1 protein.
To gain some insight into the mechanism leading to degradation of Spy1 protein
upon UV irradiation, we tested whether checkpoint kinases mediate the cue signaling of
Spy1 reduction. To address this signaling requirement for the degradation of Spy1, Chk1
and Chk2 were expressed alone or in combination with exogenous Spy1 in different cell
lines (Figure 2.3A and Figure 2.6). In each case, overall levels of Spy1 protein were
significantly depleted in the presence of over-expressed Chk1 or Chk2. To determine the
essentiality for Chk1 and Chk2 kinase activity in depleting Spy1 protein levels following
UV irradiation, U-2 OS cells were damaged in the presence or absence of chemical
inhibitors for Chk1 (UCN-01) or Chk2 (Chk2 Inhibitor II), and protein levels of Spy1
were analyzed (Figure 2.3B). Although Spy1 levels significantly accumulated after 24
hours in the presence of the Chk2 inhibitor II, no significant response was noted with the
Chk1 inhibitor, UCN-01. While over-expression of either Chk1 or Chk2 was capable of
reducing the Spy1 protein abundance, surprisingly, only inhibition of Chk2 activity
demonstrated significant events on Spy1 protein levels. Using HCT116 Chk2 null cells
exposed to 50 J/m2 of UV, levels of endogenous or ectopically expressed Spy1 protein
were monitored (Figures 2.3C and D). Interestingly, Spy1 protein was not depleted
following DNA damage under either condition. These experiments demonstrate that Spy1
protein levels can be depleted by the activation of either Chk1 or Chk2 and, surprisingly,
that Spy1 depletion following UV damage appeared to be dependent on the activity of the
Chk2 kinase.
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Figure 2.3 Chk2 triggers DNA damage-induced degradation of Spy1 protein.
A. Expression levels of Spy1 protein exposed to high levels of Chk1 and Chk2. FlagChk1 and Flag-Chk2 proteins were expressed transiently in HCT116 parental cells along
with Myc-Spy1 protein. Lysates from the respective transfectants were subjected to antiMyc immuno-blotting. The amount of actin was assessed by using an anti-actin antibody
to confirm equal protein loading. Densitometry of N=3 (right panel) is shown as mean ±
SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. B. Effects of checkpoint kinase inhibitors on
radiation-induced down-regulation of Spy1. U-2 OS cells transfected with Myc-Spy1pCS3 were either non-treated or irradiated with UV in the presence or absence of 0.1 µM
UCN-01 or 1 µM Chk2 Inhibitor II. Cells were harvested 14 hours after inhibitor addition
to monitor Spy1 protein expression via Western blotting. Densitometry of N=3 (right
panel) is shown as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. C. Endogenous
levels of Spy1 protein following exposure of HCT116 Chk2-/- cells to UV irradiation.
Cells were irradiated with 50 J/m2 of UV and harvested at the indicated time points for
Western blot analysis. Spy1 and actin protein levels were monitored by immuno-blotting.
N=3. D. Expression levels of transiently expressed Spy1 protein before and 24 hours
post-irradiation. HCT116 Chk2-/- cells were transfected with empty vector (Myc-pCS3)
or Spy1 over-expression vector (Myc-Spy1-pCS3). Cells were irradiated 24 hours posttransfection or left untreated to be examined for Spy1 levels by subjecting the whole-cell
lysates to SDS-PAGE. Densitometry of N=3 (right panel) is shown as mean ± SEM. *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001.
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2.3.4 Activation of p53 negatively regulates Spy1 protein levels.
To assess degradation of Spy1 in regulation to dynamic changes in the expression
and activity of the tumor suppressor p53, Spy1 levels, along with the phosphorylation
status of p53 protein at a critical site of activation (i.e., serine 15), were examined.
Degradation of Spy1 at later time points was accompanied with changes in
phosphorylation of p53 at serine 15 (Figure 2.4A). To further determine whether p53
expression plays a role in the regulation of Spy1 protein levels, HCT116 p53-null cells
were irradiated with 50 J/m2 of UV and levels of endogenous Spy1 was monitored. Spy1
protein levels were stable after damage in these cells (Figure 2.4B). Spy1 was then
ectopically expressed in two different p53 null cell lines, HCT116 p53-/- and Saos-2.
Spy1 protein was significantly degraded in treated Saos-2 cells (Figure 2.4.C; lower
panels), but not in the p53 null colon carcinoma cell line (Figure 2.4C; upper panels).
Despite this variance, high levels of wild-type p53 protein in different cell lines
consistently triggered significant down-regulation of Spy1 protein (Figure 2.4D and
Figure 2.7). This work supports the hypothesis that wild-type Chk2/p53 activation leads
to the targeted degradation of Spy1 to support cell cycle arrest and/or apoptosis of
damaged cells.
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Figure 2.4 Negative regulation of Spy1 protein by activated p53.
A. Correlation of Spy1 protein levels with activation of p53. Lysates of UV treated U-2
OS cells were collected at the times indicated. Levels of Spy1, p53 and p53
phosphorylation were determined using specific antibodies for Spy1, p53 and pS15-p53.
Actin was used as a loading control. N=2. B. Endogenous levels of Spy1 protein
following exposure of HCT116 p53-/- cells to UV irradiation. Cells were irradiated with
50 J/m2 of UV, harvested at times indicated and analyzed by Western blot analysis. Actin
was used as a loading control. N=3. C. Expression levels of transiently expressed Spy1
protein in UV irradiated HCT116 p53-/- (upper panels) and Saos-2 (lower panels) cells.
Cells were transfected with empty vector or Spy1 over-expression vector. 24 hours posttransfection cells were irradiated or left untreated and examined for Spy1 levels by
subjecting the whole cell lysates to SDS-PAGE followed by Western blotting.
Densitometry of N=3 (right panel) is shown as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p
≤ 0.001. D. U-2 OS cells were transfected with Myc-pCS3 and pcDNA3 as the control,
and with Myc-Spy1-pCS3, Flag-p53 or a combination of both plasmids. 24 hours after
transfection, cells were lysed and subjected to immuno-blotting. Densitometry of N=3
(right panel) is shown as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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2.4 Discussion
The DNA damage-signaling pathway is a coordinated phosphorylation-based
signaling network that has evolved to maintain genomic integrity in normal cells and
reduce cancer cell development. To mitigate the assaults of damaging agents, cells must
activate and recruit different complexes to the sites of damage. Activation of this cascade
of events, involving signaling kinases ATR and ATM [5,7], leads to activation of the cell
cycle checkpoints that are mediated by Chk1 and Chk2 proteins [5,7,29]. The main
outcome of checkpoint activation is inhibition of the activity of cyclin/Cdk complexes to
restrain cell cycle progression until damage is repaired. Therefore, to achieve a robust
block in the cell cycle, cells need to tightly control the regulators of the Cdks. As one of
these regulators, Spy1 can bind and atypically activate Cdks. When it is over-expressed,
Spy1 enhances cell proliferation and suppresses apoptotic responses to irradiation [27].
Through interaction with the Cdks, Spy1 also impairs checkpoint signaling, resulting in
the failure to activate signaling events that guarantee genomic integrity [27]. The
significance of Spy1 in the cell cycle is unquestionable as abnormally high levels of Spy1
have been associated with abnormalities in critical cell cycle events such as checkpoint
regulation and apoptosis [27]; characteristics which are advantageous to cancer cells.
This work demonstrates, for the first time, that down-regulation of the Spy1 protein is a
component of the DNA damage-signaling pathway.
Our results demonstrate that endogenous and exogenous Spy1 protein levels are
down-regulated in response to UV irradiation [30]. Although in all the cells lines tested
Spy1 levels were down-regulated, in HCT116 parental and p21-/- cells this reduction was
not significant. HCT116 cell lines are known to be deficient in mismatch repair
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mechanism [31]. This deficiency in proper DDR activation may influence proper
degradation of cell cycle regulators such Spy1. Throughout our studies, Student t test, as
a parametric method, was performed to measure the statistical significance between our
samples. However, a non-parametric method, such as Mann-Whitney, must be used to
avoid quantification bias due to mis-specifications [32]. Following UV irradiation, Spy1
levels were inversely proportional to that of the checkpoint protein p53 (Figure 2.1A).
The elevation seen in expression of SPDYA mRNA in earlier time points following UV
exposure did not correlate with the biphasic expression of Spy1 protein (Figure 2.2C). It
has been shown previously that endogenous expression of Spy1 protein is necessary in
efficient proliferation of cells treated with UV irradiation [33]. Therefore, cells may
increase the expression of SPYDA mRNA or alter its stability as part of a response to
tolerate the outcome of checkpoint signaling. Collectively, these results suggest that both
mRNA and protein levels of Spy1 are regulated during checkpoint activation by UV
irradiation.
The underlying mechanisms regulating Spy1 protein stability have been studied
previously [34,35], revealing ubiquitin/proteasome system-mediated degradation
mechanisms. It appears that degradation of Spy1 protein in different phases of the cell
cycle requires specific E3 ligases. During G2/M, degradation of Spy1 is primarily
dependent on binding to the E3 ligase Nedd4 (neuronal precursor cell-expressed
developmentally down-regulated 4), following phosphorylation of the N-terminal region
of the protein [34]. Similar to the G1/S cyclin, cyclin E, Spy1 can also be subjected to
degradation by the SCF complex (Skp, cullin, F-box containing complex), mediated by
the F-box protein Skp2 (S-phase kinase-associated protein 2) [35]. Following treatment
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with the proteasome inhibitor MG132, cells that had inhibited protein synthesis could
stabilize over-expressed Spy1 protein (Figure 2.2A) while only partially the endogenous
levels (Figure 2.2B). This suggests that a proteasome-independent mechanism may play a
role in Spy1 degradation following UV damage. After treatment of cells with the
proteasome inhibitors MG132 and/or lactacystin and the calpain inhibitor LLNL,
previous reports have shown that Spy1 levels were only sensitive to the presence of the
proteasome inhibitors [34]. Our data suggests the possibility of Spy1 degradation
following UV irradiation through other cellular proteolytic systems such as lysosomes
and calpain. Similar to other cell cycle regulators, such as p21 and p27 [36,37], Spy1
degradation following UV irradiation might also occur through Caspase-mediated
cleavage process. However, whether Spy1 degradation following UV irradiation is
proteasome-independent, inhibition of proteasome by MG132 should be primarily
assured by testing the expression of other proteins known to be degraded by the
ubiquitin/proteosome system.
Over-expression of Chk1 [38-40] and Chk2 [41-43], independent of ATR and
ATM, have been shown to lead to checkpoint activation and phosphorylation of p53.
Here, we show that high levels of these kinases were capable of down-regulating Spy1
protein (Figure 2.3A). Whether the over-expressed checkpoint kinases were also
activated in our performed experiment, and degradation of Spy1 was dependent on that,
phosphorylation status of p53 on serine 20 needs to be assessed. Pharmacological
inhibition of Chk1 or Chk2 kinase activity surprisingly revealed that only Chk2 kinase
was essential for Spy1 degradation following DNA damage (Figure 2.3B). UV irradiation
initially activates the ATR/Chk1 signaling pathway [44]; however, overlapping roles of
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ATM and ATR have been reported [44,45]. ATM activation following UV damage may
occur as a delayed response [45], potentially occurring due to double strand breaks
formed by collapsed replication forks [46]. Although the possibility of dependency of
Spy1 degradation on activation of Chk2 kinase, but not Chk1, following UV irradiation
exists, the final conclusion remains to be drawn. Whether the activities of checkpoint
kinases 1 and 2, following treatment of irradiated cells with the proper inhibitors, were
significantly inhibited, needs to be investigated. For example, phosphorylation of the
well-known Chk1/2 substrate, Cdc25C, can serve as the proper control in this
experiment. Taking advantage of HCT116 cells lacking Chk2 protein further confirmed
the possibility of dependency of Spy1 degradation on Chk2 following UV irradiation, as
cells continued to accumulate Spy1 protein (Figures 2.3C and D). Whether depletion of
Chk1 kinase would also induce stability of Spy1 protein in irradiated cells, irradiation of
cells with knock-down CHEK1 would provide the answer.
Chk1 and Chk2 activate p53 in response to DNA damage. Here, we observed that
Spy1 levels decline immediately following phosphorylation of p53 on activating
phosphorylation site, serine 15 (Figure 2.4A). Unlike Figure 2.1A, down-regulation of
Spy1 protein Figure 2.4A appeared at later time points after UV exposure; this might be
due to the use of highly passaged cells. We tested the dependency of Spy1-mediated
degradation on wild-type p53. Endogenous levels of Spy1 protein were clearly stable
following UV treatment in p53 null colon carcinoma cell line, HCT116 p53-/-, suggesting
that Spy1 degradation is a p53-dependent mechanism (Figure 2.4B). In contrast,
exogenously over-expressed protein demonstrated p53-dependence in the HCT116 p53-/line, but not in the Saos-2 line (Figure 2.4C). The osteosarcoma cell line, Saos-2, is both
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p53 and Rb null. Comparison of the results obtained from two separate cell systems,
HCT116 p53-/- and Saos-2, suggests a role for Rb in Spy1 regulation, which can further
be examined by knock-down of Rb in HCT116 p53-/- cell line. To determine whether
p53 levels could target Spy1 for degradation, p53 was over-expressed in a number of
different cell systems including U-2 OS (Figures 2.4D and 2.7). We observed a
significant, and consistent, reduction in Spy1 levels in the presence of high levels of
exogenously expressed p53. These observations support a role for p53 in targeting Spy1
protein for degradation. This also supports the hypothesis that the two major tumor
suppressors, p53 and Rb, might be involved in keeping the balance between degradation
and stability of Spy1 protein.
Taken together, these findings highlight that under cellular stress, Spy1 levels are
tightly regulated by multiple components of the DNA damage pathway, such as Chk2 and
p53 (Figure 2.5). This tight regulation by the cell cycle ensures adequate levels of Spy1
protein in damaged cells, in order to maintain checkpoint activation. Whether downregulation of Spy1 following UV exposure was dependent on checkpoint signaling
activation, or only a consequence of cell cycle blockage at a specific stage, needs to be
assessed. For example, by use of different damaging agents, which are capable of
activating checkpoint signaling molecules at different stages of the cell cycle, Spy1
stability can be tested. Moreover, to be certain of this independency, in vitro studies using
damage-activated cell extracts can be used, where Spy1 can be easily added later and its
degradation monitored.
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Figure 2.5 Regulation of Spy
Spy1 protein
n by DNA damage response pathway.
pathway
A general perspective on the regulation of Spy1 protein by DNA damage components,
components
Chk1, Chk2 and p53 proteins
proteins. See text for detailed discussion of Spy1 degradation.
degradation
P: phosphorylation, Ub: ubiquitin
ubiquitin.
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2.7 Supplementary information

Figure 2.6 Chk1- and Chk2-mediated degradation of Spy1.
Flag-Chk1 and Flag-Chk2 proteins were expressed transiently in NIH/3T3 cells along
with Myc-Spy1 protein. Lysates from the respective transfectants were subjected to antic-Myc immune-blotting. The amount of actin was assessed by using an anti-actin
antibody to confirm equal protein loading. Densitometry of N=3 (right panel) is shown as
mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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A.

B.

Figure 2.7 p53 expression reduces the stability of Spy1 protein.
A. HEK-293 and B. NIH/3T3 cells were transfected with Myc-pCS3 and pcDNA3 as the
control, and with Myc-Spy1-pCS3, Flag-p53 or a combination of both plasmids. 24 hours
after transfection, cells were lysed and subjected to immune-blotting. Densitometry of
N=3 (right panels) is shown as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Chapter 3: The Mechanism by which Spy1 Overrides DNA Damageand Replicative-Induced Senescence
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3.1 Introduction
Cellular senescence is a programmed response triggered in normal cells
experiencing various types of stimuli, including telomere erosion [1-3], DNA damage [4],
induction of oncogenes [5] and oxidative stress [6]. Replicative senescence is a
specialized cellular mechanism which occurs following an extended period of
proliferation of normal cells driven by excessive telomere erosion and dysfunction [1,7].
Senescent cells remain metabolically active, yet are irreversibly arrested in the cell cycle
[8]. They become enlarged and flattened [6], undergo drastic changes in chromatin
structure and gene expression [9], and as a result, express senescence-associated βgalactosidase activity [10]. Replicative senescence is considered to be protective against
malignant transformation since it ceases the extended propagation of cells. Cellular
senescence, as an intrinsic mechanism, also acts to prevent proliferation in response to
acute stresses, such as DNA damage, this is collectively referred to as stress-induced
premature senescence (SIPS) [11]. Mechanistically, inducers of replicative senescence
and SIPS elicit the damage signal and trigger two major tumor suppressive pathways, p53
and p16. Activation of p53, and subsequently p21 (CIP1, WAF1), is associated with the
DNA damage response (DDR) pathway, mediated by ATM/ATR and Chk1/Chk2
kinases, which can post-translationally stabilize p53, leading to its activation [12]. In
turn, transcriptional activation of the p53 target protein, p21, reduces Cdk2 kinase
activity [13].
In parallel to the p53/p21 pathway, different stimuli can also engage the p16
(INK4A) pathway to induce cellular senescence [13]. The p16 protein interacts with
Cdk4 [14] and Cdk6 [15], restricting their association with D-type cyclins, thus blocking
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their activities. The parallel p53 and p16 signaling pathways are funneled to the
regulation of the transcription factor E2F by the tumor suppressor protein, retinoblastoma
(Rb). In proliferating cells, D-type cyclins bind and activate Cdk4 and Cdk6 kinases to
target their major substrates, the Rb family of proteins, for initial phosphorylation. This
phosphorylation leads to the release of active E2F transcription factors [16,17]; therefore,
transcriptional activation of a subset of proteins required for G1/S transition, including
cyclin E [18]. Expression of cyclin E coincides with additional phosphorylation of Rb
creating the hyper-phosphorylated Rb, which fully liberates E2F molecules [19]. Upon
exposure to stimuli, expression of CKIs, such as p21 and p16, facilitates their association
with cyclin D/Cdk4/6 and cyclin E/Cdk2 complexes [19]. Thereby, they participate in
maintaining Rb in its un-phosphorylated form that can associate to transcription factors
like E2F and silence their trans-activation functions.
Inactivation of G1 phase cyclin/Cdk complexes responsible for phosphorylation
of Rb protein is the major cause of the irreversible G1 arrest in senescent cells. Negative
regulation of cyclin/Cdk complexes can be achieved by inhibitory phosphorylation of the
Cdk on threonine 14 [20,21] and tyrosine 15 [22,23] residues via Myt1 [24] and Wee1
[25] kinases, or through Cdk association with cyclin-dependent kinase inhibitors (CKIs),
such as p21. Although inhibitory phosphorylation of cyclin-dependent kinases is a rapid
and effective mechanism to induce cell cycle arrest in response to stress, it does not
account for the lack of cyclin/Cdk kinase activity in senescent cells [26]. Elevated
expression of CKIs such as p21 [27] and p16 [28] in senescent cells suggests that instead
cyclin/Cdk complexes are alternatively inactivated by their inhibitory subunits.
Coordinated regulation of these CKIs mediates the establishment and progression of

110

senescence. While p16 is up-regulated in terminal stages of senescence, p21 accumulates
progressively in cells undergoing senescence and levels decline after senescence is
achieved [28]. This suggests that senescence is maintained by p16, and that p21 is
sufficient for establishment of the arrest.
CKIs p21 and p27 bind to cyclin E/Cdk2 complexes, inhibit the complex’s kinase
activity. In turn, to promote cell cycle progression, cyclin E/Cdk2 directly down-regulates
its inhibitors. To transit from G1 to S phase, tight binding of p27 switches to a more
unbound state, where the inhibitor serves as a substrate for cyclin E/Cdk2 [29,30].
Phosphorylation of p27 on threonine 187 and its subsequent ubiquitination results in
elimination of p27 protein, mediating transition into S phase [29,30]. As a member of the
CIP/KIP family, p21 degradation reflects a similar pathway to that of p27. The cyclin
E/Cdk2 complex destabilizes p21, which requires binding of Cdk2 to the C-terminus of
p21 for phosphorylation of serine 130 [31].
Members of the atypical Cdk activator family, speedy/RINGO, can bind to and
activate Cdk1 and Cdk2, while sharing no sequence-based homology with cyclin proteins
[32,33]. The human homologue termed speedy/RINGO A (Spy1) protein is expressed
periodically during the cell cycle. Spy1 accumulates in the G1 phase and has detectable
levels in other stages [34,35]. Elevation of Spy1 protein promotes the G1/S transition,
while its depletion delays progression to S phase, suggesting a role for Spy1 in cell
proliferation through activation of G1/S Cdk, Cdk2 [34]. Atypical activation of Cdks by
Spy1 protein occurs independent of supplementary modulation of Cdks, such as
phosphorylation within the T-loop, or de-phosphorylation of threonine 14 and tyrosine 15
[36]. Another unique aspect of Spy1-mediated regulation of Cdks is that Spy1/Cdk

111

complexes are less susceptible to inhibition by CKIs such as p21 and p27 [36-38]. Direct
interaction between Spy1 and p27 leads to the enhanced cyclin E/Cdk2-mediated
phosphorylation of p27’s threonine 187 residue, resulting in the subsequent ubiquitinmediated degradation of p27 [38]. Degradation of p27 further prevents inhibition of Cdk2
by p27 and promotes G1/S transition [37]. Spy1 also plays a role in the DNA damage
response, where it enforces its Cdk-mediated functions to override checkpoint signaling,
as well as apoptosis in a p53/p21-dependent manner, therefore enhancing cell survival
[39,40].
Although anti-apoptotic effects of Spy1 in cells exposed to damage is thought to
be the mechanism by which Spy1 promotes survival, in this work we evaluate the effect
of Spy1 expression on DNA damage- and replicative-induced senescence. Spy1
expression overrides cellular senescence induced by UV irradiation as well as replicative
senescence, which is dependent on functional p53 and its downstream target protein p21.
Thus, disruption of Spy1 regulation could potentially play a role in tumor formation in
the wild-type p53 background. While elevated levels of Spy1 results in the positive
regulation of p53 expression and trans-activation, elevated Spy1 levels prevent p53 from
inhibiting growth. Furthermore, we show that Spy1 is capable of overriding p53mediated effects by down-regulating the transcriptional target of p53, p21. Spy1 interacts
with Cdk2 and p21, forms a ternary complex, and promotes phosphorylation and
degradation of the p21 protein. This facilitates activation of Cdk2 and prevents the
initiation of senescence.
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3.2 Materials and methods
Cell culture
Human foreskin fibroblasts (HFF-1; a gift from Dr. B. Mutus, University of
Windsor) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; D5796;
Sigma) supplemented with 15% fetal bovine serum (FBS; F1051; Sigma). IMR-90s
(CCL-186; ATCC) were cultured in Eagle’s Minimum Essential Medium (EMEM;
M0643; Sigma) supplemented with 10% FBS. NIH/3T3s (kindly provided by Dr. J.
Hudson, University of Windsor) were cultured in DMEM supplemented with 10% calf
serum (C8056; Sigma). Human colon carcinoma cell lines, HCT116 parental, p53-/- and
p21-/- (a gift from Dr. B. Vogelstein, Johns Hopkins School of Medicine) and the human
osteosarcoma cells, U-2OS and Saos-2 (kindly provided by Dr. J. Hudson, University of
Windsor) were cultured in McCoy’s 5A 1X (10-050-CV; Cellgro-Mediatech) with 10%
FBS. Phoenix cells (ATCC) were maintained in DMEM medium containing 10% FBS.
All media were supplemented with 1% Penicillin-Streptomycin (15070-063; Gibco) and
were incubated at 37°C in a humidified atmosphere of 5% CO2.
Plasmids
Construction of Myc-Spy1-pCS3 [34] and Flag-Spy1-pLXSN [37] vectors were
described previously. Phosphorylation mutant of p21, S130A, was generated by sitedirected mutagenesis using Flag-p21-pMT5 as the template and the oligonucleotides
targeting the specified codon. Flag-Spy1 was cloned into the pEiZ plasmid for
expression. Knock-down plasmids sh Scramble-pLKO.1 and SPDYA#2-pLKO.1 were
generated by introducing the short-hairpins, CCTAAGGTTAAGTCGCCCTCG and
TGGACATAATAGGTGATCCTT, in the pLKO.1 plasmid, respectively. The following
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plasmids were purchased from Addgene: Flag-p53-pcDNA3 (#10838), Flag-p21-pMT5
(#16240), Cyclin E-pRcCMV (#8963), pLKO.1 (#8453). The following constructs were
kind gifts: p53-responsive reporter constructs, PG13-Luc and the control MG15-Luc
from Dr. Bert Vogelstein (Johns Hopkins School of Medicine), pEiZ from Dr. Bryan
Welm (University of Utah).
Transfections
Plasmids were transiently transfected using either polyethylenimine (PEI; 408727;
Sigma) or jetPRIME (114; Polyplus transfection). In brief, for PEI transfections, 5-10 µg
of plasmid DNA was reconstituted in 50 µl/ml of 150 mM NaCl. In a separate tube, 3-5
µl of 10 mg/ml PEI was diluted in 50 µl/ml of 150 mM NaCl. Following a 5-minute
incubation, PEI was combined with the DNA solution to allow PEI/DNA complex
formation. After a 15-minute incubation, the mixture was added drop-wise to the tissue
culture plate. Cells were incubated in 5% CO2 for 8 hours then returned to normal culture
medium. Transient transfections using jetPRIME were performed by following the
manufacturer’s instruction. In brief, a total of 4 µg DNA was diluted into 200 µl
jetPRIME buffer. After vortexing the mix, 4 µl of jetPRIME was added and vortexed.
Reaction was incubated for 10 minutes at room temperature. The transfection mix was
added drop wise into the medium. Cells were incubated at 37˚C for at least 24 hours.
Generation of stable cell lines
Retrovirus was generated via transfection into Phoenix packaging cells as
previously described [41]. In brief, 8 hours post-transfection, the supernatant was
collected, sterile filtered and cells were infected with virus, supplemented with 0.025
µg/ml polybrene and incubated for an additional 16 hours. In order to select for infected
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population, 400 µg/ml G418 was added 24 hours post-infection until there were no viable
control populations. Cells were then maintained in medium containing 200 µg/ml of
G418 for a few passages.
Lenti-virus was generated via transfection into Lenti-X packaging cells. Media
was replaced 8 hours post-transfection and the culture supernatant was 24 hours later. In
order to sterilize the virus and remove cell debris, the supernatant was passed through a
0.45 µm syringe filter. The filtrate was then concentrated by centrifugation at 25,000 rpm
for 3 hours at 4°C. At 80% confluency, IMR-90 cells were infected with virus:culture
medium at an MOI of 3, in serum/antibiotic-free medium supplemented with 8 µg/ml
polybrene and incubated for 24 hours. Cells recovered for 24 hours in the appropriate
culture medium and condition prior to addition of 1 µg/ml puromycin. Cells were
cultured under selection condition for at least one week and the resistant clones were
propagated.
Cell expansion
Cumulative population doubling level (CPDL) was calculated using the formula x
= log2(NH)-log2(NS), where NH is the harvest cell number and NS is the seed cell
number. To obtain the CPDL, the population doubling level for each time period was
calculated and then added to the population doubling level of the previous one. Cell
counts were performed until cell numbers ceased to increase.
UV irradiation
Exponentially growing cells were washed once with 1X PBS (phosphate-buffered
saline) and then subjected to UVC. UVC irradiation was performed using a GS Gene
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Linker (Bio-Rad). Fresh medium was added to the culture dishes immediately after
irradiation.
Compounds and antibodies
The following antibodies were employed in this study: p53 (DO-1; sc-126; Santa
Cruz), cyclin E (1655-1; Epitomics), p21 (SX118; sc-53870; Santa Cruz), Cdk2 (M2; sc163; Santa Cruz), c-Myc (9E10; sc-40; Santa Cruz), FLAG (F1804 and F7425; Sigma),
GAPDH (0411; Santa Cruz), and actin (MAB1501R; Chemicon). Affinity purification of
rabbit anti-sera to Spy1 has been previously described [34]. Secondary antibodies used
were HRP-conjugated anti-mouse (A9917; Sigma) and anti-rabbit (A0545: Sigma) IgG.
Compounds used include cycloheximide (C7698; Sigma).
Immuno-blotting and immuno-precipitation
Samples were lysed with a 0.1% NP40 buffer supplemented with Leupeptin (5
µg/ml), Aprotinin (5 µg/ml) and Phenylmethanesulfonyl Fluoride (PMSF, 100 µg/ml).
Samples were analyzed by 10 or 12.5% SDS-PAGE then transferred to a PVDF
membrane. Primary antibodies were applied and incubated at 1:200 to 1:1000 dilutions.
Secondary antibodies were used at 1:10,000. Proteins were detected via treatment with
Perkin-Elmer Enhanced Chemiluminscence reagent and quantified using FlourChem
HD2 software (AlphaInnotech; Perkin Elmer).
Immuno-precipitation reactions were carried out with equal amounts of whole cell
extracts (500 µg). Precipitation of the antigen-antibody complex was accomplished by
over-night rotation at 4°C in the presence of protein G sepharose beads (17-0618-01; GE
Healthcare). Precipitated beads were washed three times in 0.1% NP-40 (Nonidet P-40)
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lysis buffer. Laemmli sample buffer (101-0737; BioRad) was added to the bead pellets,
and samples were heated for 5 minutes at 95°C prior to gel electrophoresis.
Kinase activity
Cells were washed with cold 1X PBS, lysed in 0.1% NP-40 lysis buffer and
centrifuged at 10,000 g for 10 minutes. 500 µg of protein was incubated overnight at 4 °C
in 500 µl of 0.1% NP-40 lysis buffer with 10 µg of anti-Cdk2 antibody followed by a 2hour incubation with protein G sepharose beads (17-0618-01; GE Healthcare). Immunocomplexes were washed 3x with 1 ml 0.1% NP-40 buffer, aspirated to 50 µl and 50 µl of
2X kinase assay buffer [50 mM Tris-HCl (pH 7.4), 20 mM EGTA, 10 mM MgCl2 1 mM
DTT, 1 mM sodium orthovanadate] containing 5 µCi of [γ-32P] ATP (PerkinElmer) was
added. Upon addition of 2 µg of histone H1 (382150; Calbiochem) the mixtures were
incubated at 30 °C for 30 minutes. Reactions were terminated with 4X sample buffer,
boiled for 5 minutes and subjected to 12.5% SDS-PAGE. Bands were exposed to a
tritium-sensitive phosphor-imaging screen and then quantified with the OptiQuant
software.
Luciferase activity
Cells were harvested 24 hours post-transfection with the appropriate constructs,
MG15-Luc and PG13-Luc, with or without Spy1 and p53. Lysates were mixed with
Bright-glo reagent (E2620; Promega) and the luminescence spectra of the samples were
measured using a plate reader (Wallac Victor 1420; PerkinElmer 3TM-1420).
Real-time PCR
Total RNA was isolated using a commercial mini-preparation kit (RNeasy™,
Qiagen). First strand cDNA was synthesized using SuperScript™ II Reverse
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Transcriptase (18064; Invitrogen). Relative quantities of mRNA expression were
analyzed using real-time PCR (ABI 7300 Sequence Detection System, Applied
Biosystems). In this study, CDKN1A, and 18SRNA levels were quantified by Taqman
expression assays Hs99999142_m1 and Hs99999901_s1, respectively.
Statistical analysis

Student’s t test was employed using Statistica software. All results are expressed
as mean ± SEM from at least three individual experiments and differences were
considered significant at p values of ≤ 0.05.
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3.3 Results
3.3.1 Spy1 suppresses cellular senescence and its depletion leads to proliferation
defects.
Spy1 levels decrease in response to different doses of UV (Figure 2.1A). Elevated
levels of Spy1 have been shown to disturb checkpoint activation [39]. We aimed to
explore the extent to which Spy1 mediates effects on cellular responses to different
stimuli. Throughout the dose and time range of UV irradiation, it was notable that Spy1
over-expression continued to have a significant effect on cell survival (Figure 3.1A).
Spy1 promoted survival at even higher doses of irradiation after 72 hours of UV
treatment, generating significantly more live proliferating cells than the control.
Previous studies have established that highly expressed Spy1 is capable of
overriding DNA damage-induced apoptosis in a p53 dependent manner [39]. Here, we
observed that Spy1 over-expressing cells were more prone to stress. To understand
whether this resistance was due to the inhibition of p53-mediated apoptosis by Spy1 or
dependent upon other misregulations, we intended to investigate Spy1 regulation of other
pathways mediated by p53 in response to UV irradiation. The p53 protein has always
been linked to, and is one of the hallmarks of, cells undergoing senescence [5]. We used
IMR-90 cells (human lung fibroblasts) to test the effects of Spy1 protein on cellular
senescence. Stable IMR-90 cells were generated to stably over-express Spy1 or the
vector-control pEiZ. Three individual control or Spy1 colonies were cultured to
senescence stage. Cell counts were taken via trypan blue exclusion to calculate the
cumulative population doubling (CPD) of each population (Figure 3.1B). Spy1 cells
remained proliferative and had not reached plateau at up to day 70, while control cells
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stopped growing after 7 weeks in culture (Figure 3.1B). Using stable HFF-1 cells overexpressing vector control or Spy1 similar results were obtained. Control or Spy1 colonies
were cultured to senescence. Cell counts were taken via trypan blue exclusion to
determine the mean doubling time of each population (Figure 3.7A) and protein
expression was monitored by western blot analysis (Figure 3.7B). Over four separate
experiments, cells over-expressing Spy1 demonstrated a significant delayed entry into
senescence by at least 20 cell passages (Figure 3.7A). Cell lysates obtained over several
passages revealed that the levels of endogenous Spy1 protein were down-regulated when
p53 levels were rising (Figure 3.7B), similar to what we previously observed in Figure
2.1A. In HFF-1 cells over-expressing Spy1, however, high levels of Spy1 delayed
accumulation of p53.
By considering that over-expression of Spy1 protein can inhibit activation of
checkpoint signaling and delays senescence appearance, down-regulation of Spy1 protein
levels could potentially lead to proliferation defects in aging cells, similar to what has
been observed in cells damaged with UV irradiation [40]. We generated stable IMR-90
cells infected with a scrambled sequence as the control or sh SPDYA constructs. The
CPDLs were measured over 50 days. Growth curves of three individual experiments
revealed that knock-down of Spy1 resulted in a significant proliferation defect in IMR-90
cells with cells entering senescence faster than the control cells. At each passage,
morphology of the cells was monitored for the visible signs of senescence by microscopic
analysis.
Collectively, our data demonstrates that cells over-expressing Spy1 continued to
actively proliferate far after the control cells had reached the senescent state. Also,
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elevated Spy1 protein levels can bypass senescence checkpoints in human fibroblasts by
delaying the expression of p53, establishing the essentiality for the down-regulation of
Spy1 during replicative senescence. Furthermore, our data shows that knock-down of
Spy1 leads to proliferation defects in cells undergoing replicative senescence,
emphasizing the necessity of Spy1 expression in proliferating cells.
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Figure 3.1 Spy1 overcomes DNA damage and replicative senescence effects.
A. NIH/3T3 cells infected with empty vector or Spy1 were treated with varying doses of
irradiation as indicated in the legend. Number of living cells was assessed via trypan blue
analysis over time. Data points represent mean ± SEM from three individual experiments.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. B. CPDLs of vector control cells or Spy1 overexpressing cells until senescence were monitored using trypan blue analysis to determine
cell numbers at each passage of the cells stably over-expressing Spy1 in comparison to
control cells. Data points represent mean ± SEM from three individual experiments. *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001. C. CPDLs of sh control cells or sh SPDYA cells until
senescence were monitored using trypan blue analysis to determine cell numbers at each
passage. Data points represent mean ± SEM from three individual experiments. *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001.
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3.3.2 Spy1 increases the stability and activity of p53 protein.
Levels of Spy1 protein were significantly depleted in the presence of overexpressed p53 (Figure 2.4D). From this data it was also observed that high levels of Spy1
may also have an effect on p53 levels. Therefore, we quantified the effects of Spy1 on
p53 protein levels and its transcriptional activity. Throughout our studies, Spy1 overexpression markedly increased p53 protein levels (Figures 3.2A and 3.8). p53 protein
levels were further studied in the presence of cycloheximide, with and without Spy1, to
determine whether the stability of p53 protein levels required de novo protein synthesis
when Spy1 is present. As established in (Figure 3.2B), p53 protein levels were higher
even after 4 hours of cycloheximide (CHX) treatment in the presence of Spy1. Calculated
half lives of the p53 protein in the presence and absence of Spy1 were very similar
(Figure 3.2B; right panels). However, the slopes of the sample sets are significantly
different, confirming that Spy1 influences the degradation rate of the p53 protein. To test
the activity of p53, a p53 null cell line, HCT116 p53-/-, was transfected with the
appropriate constructs and a set of reporter constructs for p53. The reporter set used was a
luciferase construct (PG13-Luc) containing 13 copies of the p53 consensus binding
sequence, and a control reporter plasmid (MG15-Luc) with 15 copies of the scrambled
sequence (Figure 3.2C). Intriguingly, increase in p53 luciferase activity was observed
when Spy1 protein was expressed; indicating that high levels of Spy1 can enhance p53
activity. Since measuring CDKN1A (p21) mRNA levels is an accepted measure of the
functional status of p53 [42], CDKN1A levels were measured in cells over-expressing
p53, with or without Spy1 (Figure 3.2D). The significant induction of p21 mRNA
expression in cells where Spy1 is co-expressed with p53 further supports that p53 activity
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is enhanced with Spy1. Together, these results suggest the existence of a feedback loop
between Spy1 and p53, whereby under stress responses p53 promotes degradation of
Spy1 (Figure 2.4D) to ensure that cell cycle arrest, or apoptosis, can occur. Under
conditions where Spy1 protein accumulates, this is seen as a stress response for the cell
prompting increases in the level and activity of p53. This feedback loop ensures that
Spy1 protein levels are maintained at appropriate levels in normal cells.
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Figure 3.2 Spy1-mediated p53 stability and activity.
A. HFF-1 cells were transfected with Myc-Spy1-pCS3, Flag-p53 or a combination of
both plasmids. Cells were lysed 24 hours post-transfection and subjected to immunoblotting. Densitometry of N=3 (right panel) is shown as mean ± SEM. *p ≤ 0.05, **p ≤
0.01, ***p ≤ 0.001. B. HFF-1 cells were transfected with p53 alone or in combination
with Myc-Spy1-pCS3, followed by cycloheximide treatment (CHX; 25 µg/m). Cells were
harvested at the indicated time points after CHX treatments to monitor p53 protein
stability in the presence and absence of Spy1. Densitometry of N=3 (right panel) is
shown as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. C. HCT116 p53 -/- cells
were transiently transfected with empty vector (pcDNA3) or Flag-p53-pcDNA3 in
combination with Myc-pCS3, Myc-Spy1-pCS3, PG13-Luc and MG15-Luc constructs.
Luciferase activity of the lysates were measured using a luciferase reporter assay at 24
hours post-transfection. Luciferase activity is expressed as the fold of normalized
luciferase activity (normalized to control MG15-Luc) with p53 or p53+Spy1 to the
control. The relative luciferase activity of control was assigned a value of 1. Data points
represent mean ± SD from three individual experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤
0.001. D. Histogram showing quantitative real-time PCR analysis of the mean mRNA
expression of CDKN1A gene in NIH/3T3 cells over-expressing p53 or Spy1 and p53
together. Represented data are mean ± SEM of three individual experiments. *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001.
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3.3.3 Spy1 requires p53 and p21 to induce its survival/proliferative function
following UV irradiation.
The question still remaining is that how Spy1 is mechanistically overriding
cellular processes such as DNA damage and replicative senescence. To address this
question, we transfected the NIH/3T3 cells with Spy1, p53 or a combination of both, and
assessed overall cell growth via trypan blue analysis (Figure 3.3A). Spy1 significantly
bypassed the anti-proliferative effects of p53 directly; significantly enhancing cell
numbers to greater than that of the control p53. To determine whether Spy1 proliferative
effects are dependent on p53, we compared the U-2 OS cell line with the p53 null variant
Saos-2. When over-expressing control or Spy1 in the presence or absence of 50 J/m2
UV, we noted that Spy1 significantly enhanced cell numbers in the U-2OS cells, both
before and after UV treatment (Figure 3.3B; left panel). However, in the p53-null line,
Spy1 exerted significant proliferative/survival effects on cells only prior to UV treatment
(Figure 3.3B; right panel). Thus, we conclude that, while the proliferative effects of Spy1
are independent of p53 status, the ability of Spy1 to override the DDR is dependent on
overriding p53 effects. These data support a mechanism whereby Spy1 may override
functional checkpoints in healthy cells, yet is also capable of enhancing proliferation
independent of influencing p53, which is important given that more than 50% of all
human cancers are p53-mutated/deleted [43].
It has been demonstrated that Spy1 overrides the DNA damage-mediated
apoptotic events in a p21-dependent manner [40]. Utilizing the HCT116 p21+/+ and p21/- cell systems, we tested the effects of Spy1 on cell survival/proliferation using doses of
UV previously performed experiments (Figure 3.3C). In the presence of p21, over-

128

expression of Spy1 significantly enhanced cell proliferation in the presence and absence
of UV damage (Figure 3.3C; left panel), however, these effects were not seen in the p21
null cell system (Figure 3.3C; right panel). This indicates that Spy1-induced proliferation
and survival are dependent on p21. Interestingly, in contrast to previously published data
[39,40], effects on cell death seen at this dose demonstrated no statistically significant
changes (Figure 3.9). Taken together, following UV irradiation Spy1-induced
proliferation and survival are dependent on p53 and p21 proteins.
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Figure 3.3 Dependency of Spy1 protein on p53 and p21 to execute its
survival/proliferative function following UV irradiation.
A. Number of alive NIH/3T3 cells after 48 hours of transduction with Myc-pCS3 and
pcDNA3 as the control, and combinations of Myc-Spy1-pCS3 and Flag-p53, were
assessed by trypan blue analysis. Data points represent mean ± SEM from three
individual experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. B and C. Cell count
analysis of the U-2OS, Saos-2 cells (B), and HCT116 p21+/+ and HCT116 p21-/- cells
(C) transfected with either Myc-pCS3 or Myc-Spy1-pCS3. Cells were either mock
treated or UV irradiated (50 J/m2). The total numbers of live cells were assessed via cell
counting using trypan blue staining. Data points represent mean ± SEM from three
individual experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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3.3.4 Spy1 regulation of p21.
It is known that p21 protein can be targeted for degradation by Cdk2 through
phosphorylation on C-terminal residue, S130 [31]. Spy1 has been previously shown to
directly regulate Cdk2-mediated phosphorylation of the p21 family member p27 [38],
which harbors structural and functional similarities with regards to binding interactions
with Cdks [44]. Hence, we studied p21 protein levels in cells over-expressing Spy1. We
found a considerable decrease in p21 protein abundance in the presence of Spy1 (Figure
3.4A). It has been reported that cyclin E binds to the N-terminal cyclin-binding motif of
p21 with greater affinity than the C-terminal motif [45]. This interaction, which is
followed by Cdk2 recruitment, provides the stability of p21 protein. In the presence of
excess levels of cyclin E/Cdk2, however, the complex interacts with the C-terminal motif
and promotes p21 phosphorylation and subsequent degradation [31]. To examine whether
Spy1-induced degradation of p21 is similar to p21 degradation by classical cyclin E, we
transfected the HFF-1 cells with similar amount of constructs over-expressing cyclin E
and/or Spy1, along with p21 in the presence of the protein synthesis inhibitor
cycloheximide. As it was shown previously [31], cyclin E/Cdk2 complex could stabilize
p21 protein, presumably, through its interaction with the N-terminus of the p21 protein
(Figure 3.4B; left lanes); however, Spy1 destabilized p21 protein. Similar to Figure 3.4A,
Spy1 significantly reduced the abundance of p21 protein 24 hours after the time of
transfection (t:0), and at all time points following CHX treatment, resulting in
considerably less p21 protein (Figure 3.4B; right lanes). Hence, Spy1 induces degradation
of the p21 protein in a manner different than cyclin E.
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Figure 3.4 Induction of p21 degradation by Spy1 protein.
A. HFF-1 cells were transfected with combinations of Myc-Spy1-pCS3, Flag-p21 or
controls. Following a 24-hour incubation, transfected cells were lysed and monitored for
Spy1 and p21 protein levels. Densitometry of N=3 (right panel) is shown as mean ±
SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. B. HFF-1 cells were transfected with Flagp21 and with either cyclin E or Spy1 expression plasmids, as indicated. 24 hours posttransfection, cells were treated with 25 µg/ml of CHX, lysed at the indicated times after
CHX treatment and immuno-blotted for p21 using Flag antibody. Densitometry of N=3
(right panel) showing the rates of p21 degradation in the presence of cyclin E and Spy1 is
shown as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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3.3.5 Spy1 inhibits p21 function.
It has been noted previously that Spy1-mediated Cdk2 activation was independent
of inhibition by p21 [36]. Figure 3.4 shows that Spy1 is capable of destabilizing p21
protein (Figure 3.4). Hence, we studied the binding between Spy1, Cdk2, and p21 by an
immuno-precipitation assay. Transfection of HFF-1 cells with plasmids expressing Flagtagged p21 alone, or its co-expression with cyclin E or Spy1 was carried out and the
complex was immuno-precipitated using Flag antibody. Similar to cyclin E protein, Spy1
was found in complex with Cdk2 and p21 (Figure 3.5A; left panels). Cdk2 kinase activity
was assessed in the presence of Spy1, p21 or Spy1 and p21 in combination, by measuring
phosphorylation of histone H1 (Figure 3.5B). We confirmed that indeed Cdk2 kinase
remains active in the presence of Spy1 despite expression of p21.
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Figure 3.5 Spy1/Cdk2 complex is resistant to inhibitory effects of p21.
A. HFF-1 cells were transfected with Flag-p21 and either cyclin E or Myc-Spy1, as
indicated. Cell lysates were prepared 24 hours post-transfection and immuno-precipitated
with Flag antibody to isolate cyclin E/Cdk2/p21 or Spy1/Cdk2/p21 complexes. Isolated
complexes (left panels; N=1) and the corresponding lysates (right panels; N=4) were
resolved on a 12.5% polyacrylamide gel. B. HEK-293 cells were transfected with the
indicated constructs. Cdk2 was immuno-precipitated and incubated in kinase buffer,
containing histone H1 as the substrate to assess its activity and then resolved on a 12.5%
polyacrylamide gel. Incorporation of
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P, as determined by phosphor-imaging, is

indicated in the top panel. Cdk2 IP as determined by immuno-blotting is indicated in the
lower panel.
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3.4 Discussion
Cdks are important mediators of cellular responses to stimuli such as DNA
damage and telomere dysfunction. Many levels of regulation impact the activity of Cdks
to ensure tight control of cell cycle events. Activation of checkpoint signaling in response
to any kind of damage to DNA, either by genotoxic stress or intrinsic processes, stunts
progression of the cell cycle, allowing for repair. If overwhelming damage occurs, cells
re-enforce these inhibitory checkpoints to trigger irreversible arrest (senescence) or
apoptosis.
p53-mediated inhibition of Cdks, through expression of the Cdk inhibitor p21,
provides a mechanism to establish a prolonged arrest in cells faced with extensive DNA
damage or those undergoing senescence. Slippage from this regulation leads to defective
checkpoints, which are a feature of the majority of human cancers. The atypical Cdk
activator Spy1 is known to bind to and prevent the inhibitory function of the Cdk
inhibitor p27, resulting in relief of cell cycle arrest [37,38]. In this study, we report a role
for Spy1 expression in the induction of senescence by UV irradiation and exhaustive
replication. We show that over-expression of Spy1 blocks the outcome of checkpoint
activation, demonstrated by survival of NIH/3T3 cells stably expressing Spy1 protein
when exposed to different doses of UV irradiation (Figure 3.1A). Using different
fibroblast cell lines stably expressing Spy1, we demonstrate that high levels of Spy1
overcome replicative senescence by delaying p53 expression (Figures 3.1B and 3.7). This
suggests a requirement for controlled regulation of Spy1 protein during cellular
senescence. Furthermore, proposing that as in replicating fibroblast cells, overriding the
DNA damage effects by Spy1 might be due to delay or inhibition of the tumor
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suppressive response, i.e., cellular senescence. Utilizing the same cell system stably
expressing sh RNA against SPDYA mRNA, we observed a delay in proliferation of these
cells, further confirming the necessity of Spy1 expression to maintain proliferation
efficiently (Figure 3.1C). These results indicate that proper regulation of Spy1 protein
provides a balance between proliferation and stress-induced programs such as
senescence.
Checkpoint activation is regulated through the key tumor suppressor protein p53.
Our data demonstrates that Spy1 expression modulates p53 stability and activity (Figure
3.2). Further investigation is required into elucidating whether increased stability of p53
protein is due to direct inhibition of Mdm2 by induced expression of ARF protein, or if it
occurs via post-translational modification of the protein at critical sites. The higher
activity of p53 protein measured by using reporter constructs (Figure 3.2C) was further
limited to the expression of the well-known p53 target gene, CDKN1A (p21) (Figure
3.2D). Elevated CDKN1A mRNA levels induced by Spy1 reflect the fact that high levels
of Spy1 act as a stress signal on cells, similar to the cellular response to expression of the
onco-proteins.
Previous reports dissected the mechanism by which Spy1 regulates the DDR and
have established that this regulation, at least in part, is mediated by anti-apoptotic
function of Spy1 [39,40]. Using isogenic HCT116 cells modified to be p53 or p21 null,
they confirmed that Spy1-mediated effects regulating the DDR pathway require p53 and
its downstream target p21 protein [40]. Here we show that following UV irradiation,
Spy1-mediated effects on cell survival/proliferation are dependent on p53 and p21
proteins (Figure 3.3), suggesting that misregulation of Spy1 protein in tumors with wild-
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type p53 may contribute to abnormal cell proliferation. Although the requirement for p53
and p21 proteins for the proliferative function of Spy1 was in agreement with the
previously published data, we did not observe any significant prevention of cell death by
over-expression of Spy1 protein (Figure 3.9). Our results implicate the possibility of
Spy1 regulation of other cellular processes in response to DNA damage; these effects
may be dependent on the dose and timing of the damage response.
The necessity for p21 in Spy1-mediated regulation of the DNA damage response
and the fact that Spy1/Cdk complexes are less susceptible to inhibition by CKIs provoked
us to evaluate the regulation of p21 by Spy1 protein. We observed that high levels of
Spy1 protein promoted the degradation of p21 (Figure 3.4). Cyclin E/Cdk2 complexes,
which can be inhibited by p21 function, are therefore incapable of phosphorylation and
degradation of p21 [31]. However, excess amounts of Spy1 protein can bind to p21
protein and suppress p21’s inhibitory function, thereby activating Cdk2 (Figure 3.5B).
The interaction between Spy1 and p21 protein, similar to p27, may be through the
binding of Spy1 to the Cdk-binding domain of p21, which further promotes
phosphorylation of the CKI by the cyclin E/Cdk2 complex. However, if binding is
through the occupation of the cyclin-binding motif located in the N-terminus of the p21
protein, this would result in binding of cyclin E/Cdk2 complexes to the C-terminus of the
protein, leading to its subsequent phosphorylation and degradation. Another possibility is
that in comparison to cyclin E protein, Spy1 might have higher affinity for the C-terminal
cyclin-binding domain of p21. Therefore, phosphorylation of p21 may occur directly via
Spy1/Cdk2 complexes. Combinational studying of Spy1 binding to p21 mutants lacking

138

cyclin- or Cdk-binding domain, and knock-down of cyclin E protein, would provide a
definite answer to these possibilities.
It is well-known that p21 protein is a negative regulator of p53-dependent and
independent apoptosis [46,47]. Here, we show that Spy1-mediated effects on DNA
damage response are dependent on both p53 and p21. We also demonstrate that Spy1
binds with Cdk2 and p21 protein and suppresses the inhibitory function of p21, which is
required in cellular processes such as senescence. Taken as a whole, these results suggest
that Spy1 regulation of DNA damage response is mediated by anti-senescence role of
Spy1 through degradation of p21 protein (see Figure 3.6).
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Figure 3.6 Spy1 regulation of senescence
senescence.
Schematic representation of the regulation of cellular senescence by Spy1.
Spy See text for
detailed discussion. P: phosphorylation
phosphorylation.
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3.7 Supplementary information

A.

B.

Figure 3.7 Spy1 overcomes replicative senescence in human fibroblasts.
A. Population doublings until senescence were monitored using trypan blue analysis to
determine cell number at each passage of the cells stably over-expressing Spy1 in
comparison to control cells. B. Stable HFF-1 cells at different passages (p) indicated at
the top of each lane were subjected to immuno-blotting to monitor protein levels of Spy1,
p53, and GAPDH, as the loading control.
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A.

B.

C.

Figure 3.8 Spy1 stabilizes p53 protein.
HEK-293 (A), NIH/3T3 (B), and U-2 OS (C) cells were transfected with Myc-Spy1pCS3, Flag-p53 or a combination of both plasmids. Cells were lysed 24 hours posttransfection and subjected to immuno-blotting. Densitometry of N=3 is shown as mean ±
SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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A.

B.

Figure 3.9 Spy1 expression does not prevent cell death following UV irradiation.
Cell count analysis of the (A) U-2OS and Saos-2 cells, and (B) HCT116 p21+/+ and
HCT116 p21-/- cells transfected with either Myc-pCS3 or Myc-Spy1-pCS3. Cells were
either mock treated or UV irradiated (50 J/m2). The total numbers of dead were assessed
via cell counting using trypan blue staining. Data points represent mean ± SEM from
three individual experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Chapter 4: Mutational Analysis of the Potential Phosphorylation Sites
of Spy1 Protein.
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4.1 Introduction
The human Spy1 is a key player in regulation of cell proliferation [1]. Spy1 is
widely expressed in human tissues and cell lines [1,2], elevated in human cancers such as
breast ductal carcinoma [3] and suggested as a prognostic parameter for hepatocellular
carcinoma [4]. Additionally, in vivo studies using a mouse model showed that Spy1 overexpression accelerated mammary tumorigenesis [5]. To employ its proliferative effects,
Spy1 directly binds to Cdk1 and 2 [2] and induces Cdk activation [1]. The proliferative
function of Spy1 is not solely attributed to Cdk activation. Spy1 directly binds to the Cdk
inhibitor p27 and promotes its phosphorylation that is required for the degradation of the
protein [6,7]. Subsequently, when the inhibitory effect of p27 on Cdk2 is removed, Cdk2
becomes activated to allow rapid G1/S progression [6]. In the case of damage, ectopic
expression of Spy1 has been shown to override cell cycle checkpoint activation [8,9].
Spy1 expression has also been shown to suppress the phosphorylation of ATR (ataxia
telangiectasia and Rad3-related) substrates such as H2AX (at serine 139), RPA32
(replication protein A, subunit 32) (at serines 4 and 8), and Chk1 (at serines 317 and 345)
[9]. As a result of such impairments in ATR signaling, Spy1 bypasses repair and the
replication and G2/M checkpoints, thereby promoting cell cycle progression. Spy1 is
required to bind and activate Cdk2 to suppress functional effects of ATR [9]. Similarly,
its association with Cdk2 is described to be necessary in its regulation of apoptosis [9].
When challenged with UV irradiation, Spy1 over-expression enhances cell survival by
preventing the activation of apoptosis through the inhibition of Caspase-3 (cysteineaspartic protease 3) cleavage [9]. Apoptotic inhibition by expression of Spy1 is also
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dependent on p53 and p21 tumor suppressors [8]. This suggested that Spy1/Cdk2
complex may interfere with p53/p21 pathway to protect cells from apoptosis.
Collectively, previous works suggest that Spy1 expression can control cell
survival and proliferation by interfering with main cellular mechanisms such as repair,
checkpoint signaling, and apoptosis. Therefore, its levels must be tightly regulated to
avoid interference with proper responses to ongoing cellular processes. We have
previously shown Spy1 is degraded following UV irradiation. Here, we show that Spy1
protein is phosphorylated following UV irradiation as well as in the presence of
ectopically expressed p53. We hypothesize that its phosphorylation is required for
degradation of the protein following checkpoint activation and may occur via Chk1 or
Chk2 kinases.
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4.2 Material and methods
Cell culture
The human osteosarcoma cell line, U-2OS, (kindly provided by Dr. J. Hudson,
University of Windsor) was cultured in McCoy’s 5A 1X medium (10-050-CV; CellgroMediatech), supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were
maintained in an atmosphere of 5% CO2 at 37˚C.
Plasmids
Myc-Spy1A-pCS3 [1] vector was described previously. Flag-p53-pcDNA3
construct was purchased from Addgene (#10838). Spy1 mutant constructs were generated
by site-directed mutagenesis using the appropriate primers listed in Table 4.1.
Transfections
Plasmids were transiently transfected using jetPRIME transfection reagent
(CA89129-922; VWR). In brief, a total of 4 µg DNA was diluted in 200 µl of jetPRIME
buffer. After vortexing the mix, 4 µl jetPRIME was added and vortexed. Reaction was
incubated for 10 minutes at room temperature. The transfection mix was added drop-wise
into the medium. Cells were incubated at 37˚C for at least 24 hours..
UV irradiation
Exponentially growing cells were washed once with PBS and then subjected to
UVC. UVC irradiation was performed using a GS Gene Linker (Bio-Rad). Fresh medium
was added to the culture dishes immediately after irradiation.
Antibodies
The following antibodies were used: c-Myc (9E10; sc-40; Santa Cruz), actin
(MAB1501R; Chemicon), and HRP-conjugated anti-mouse (A9917; Sigma) IgG.
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Immuno-blotting and immuno-precipitation
Samples were lysed with 0.1% NP-40 buffer supplemented with Leupeptin (5
µg/ml), Aprotinin (5 µg/ml), PMSF (100 µg/ml), and Sodium orthovanadate (1mM).
Samples were analyzed by 10% SDS-PAGE then transferred to a PVDF membrane. Antic-Myc and Anti-actin antibodies were used at 1:1000 dilution and the anti-mouse IgG
antibody was applied at 1:10000 dilution. Proteins were detected via treatment with
Perkin-Elmer Enhanced Chemiluminescence reagent and quantified using FlourChem
HD2 software (AlphaInnotech; Perkin Elmer).
Immuno-precipitation reactions were carried out with equal amounts of whole cell
extracts (500 µg). Precipitation of the antigen-antibody complex was accomplished by
over-night rotation at 4°C in the presence of protein G sepharose beads (17-0618-01; GE
Healthcare). Precipitated beads were washed three times in 0.1% NP-40 (Nonidet P-40)
lysis buffer. Laemmli sample buffer (101-0737; BioRad) was added to the bead pellets,
and samples were heated for 5 minutes at 95°C prior to gel electrophoresis.
In vivo [32P]-orthophosphate labeling
U-2 OS cells were cultured and transfected with the appropriate constructs. 24
hours after transfection, one plate was subjected to UV irradiation and reincubated at
37°C for an additional 12 hours. Cells were then washed with phosphate-free DMEM
(11971-025; GIBCO) and incubated with the same medium. 1 hour later, [32P]orthophosphate (PerkinElmer), with final concentration of 1 mCi/ml, was added into each
plate for 4 h at 37°C. Labeling was stopped by washing the cells with ice-cold PBS. Cells
were lysed and immune-precipitated with c-Myc antibody. Immuno-precipitants were
washed and subjected to SDS-PAGE. Bands transferred to PVDF membrane were
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exposed to a tritium-sensitive phosphor-imaging screen and quantified with the
OptiQuant software.
Statistical analysis
Student’s t test was employed using Statistica software. All results are expressed as mean
± SEM from at least three individual experiments and differences were considered
significant at p values of ≤ 0.05.
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Oligo number
S200A:
B273
B274
S222A:
A429
A430
S200A/S222A:
B274
A429
A430
T224A:
B298
B299
S229A:
B296
B297

Sequence
5'-TCTGGCAAAGAGAACGTGCTGTTCATCACAGTGGA-3'
5'-TCCACTGTGATGAACAGCACGTTCTCTTTGCCAGA-3'
5'-CTGCCCCGGGGACCTGCTGCCACACCAG-3'
5'-CTGGTGTGGCAGCAGGTCCCCGGGGCAG-3'
5'-TCTGGCAAAGAGAACGTGCTGTTCATCACAGTGGA-3'
5'-TCCACTGTGATGAACAGCACGTTCTCTTTGCCAGA-3'
5'-CTGCCCCGGGGACCTGCTGCCACACCAG-3'
5'-CTGGTGTGGCAGCAGGTCCCCGGGGCAG-3'
5'-CGGGGACCTAGTGCCGCACCAGTAGATTGTTC-3'
5'-GAACAATCTACTGGTGCGGCACTAGGTCCCCG-3'
5'-TGCCACACCAGTAGATTGTGCGCTCTGTGGTAAAAAAAG
AAG-3'
5'-CTTCTTTTTTTACCACAGAGCGCACAATCTACTGGTGTGG
CA-3'

S222A/S229A:
A429
A430

5'-CTGCCCCGGGGACCTGCTGCCACACCAG-3'
5'-CTGGTGTGGCAGCAGGTCCCCGGGGCAG-3'
5'-TGCCACACCAGTAGATTGTGCGCTCTGTGGTAAAAAAAG
B296
AAG-3'
5'-CTTCTTTTTTTACCACAGAGCGCACAATCTACTGGTGTGG
B297
CA-3'
S222A/T224A/S229A:
A429
5'-CTGCCCCGGGGACCTGCTGCCACACCAG-3'
A430
5'-CTGGTGTGGCAGCAGGTCCCCGGGGCAG-3'
5'-TGCCACACCAGTAGATTGTGCGCTCTGTGGTAAAAAAAG
B296
AAG-3'
5'-CTTCTTTTTTTACCACAGAGCGCACAATCTACTGGTGTGG
B297
CA-3'
B335
5'-GGGGACCTGCTGCCGCACCAGTAGATTGTG-3'
B336
5'-CACAATCTACTGGTGCGGCAGCAGGTCCCC-3'
S260A:
B275
5'-AGCAGGGGTGACAGAAAAACATGCTCAGGACTCAT-3'
B276
5'-ATGAGTCCTGAGCATGTTTTTCTGTCACCCCTGCT-3'
S276A:
5'-AATGGACATAATAGGTGATCCTGCGCAAGCTTATACTGG
B277
TTCTGAAG-3'
5'-CTTCAGAACCAGTATAAGCTTGCGCAGGATCACCTATTA
B278
TGTCCATT-3'
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S260A/S276A:
B275
B276
B277
B278

5'-AGCAGGGGTGACAGAAAAACATGCTCAGGACTCAT-3'
5'-ATGAGTCCTGAGCATGTTTTTCTGTCACCCCTGCT-3'
5'-AATGGACATAATAGGTGATCCTGCGCAAGCTTATACTGG
TTCTGAAG-3'
5'-CTTCAGAACCAGTATAAGCTTGCGCAGGATCACCTATTA
TGTCCATT-3'

Table 4.1 Primers used to generate SPDYA mutants.
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4.3 Results
4.3.1 Spy1 protein is phosphorylated by DDR components.
In Figure2 2.1 and 2.4, we observed that Spy1 protein is destabilized following
UV irradiation and when over-expressed with p53. Previously published data have
established the requirement of phosphorylation for degradation of Spy1 protein [10]. To
assess post-translational modification of Spy1 prior to its degradation in response to DNA
damage as well as p53 activation, we performed a [32P]-orthophosphate labeling of Spy1.
U-2 OS cells were transfected to over-express either Spy1 or Spy1 and p53. Cells overexpressing Spy1 were then treated with 50 J/m2 of UV for 12 hours. After UV treatment,
32

P was incorporated and Spy1 was immuno-precipitated from the lysates to assess the

phosphorylation status of each sample (Figure 4.1). By quantification of 32P incorporation
into Spy1, net phosphorylation of Spy1 was found increased 1.7 and 3.2 fold by UV
irradiation and ectopically expressed p53, respectively (Figure 4.1; right panel). These
values were not statistically analyzed (N=1); however, they were increased relative to the
baseline in untreated sample. Therefore, Spy1 is phosphorylated by UV exposure and
activated p53 prior to its degradation.
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Figure 4.1 Phosphorylation of Spy1 protein prior to its proteasomal degradation.
[32P]-orthophosphate labeling of Spy1 following treatment with UV and high levels of
p53.

32

P was incorporated into immuno-precipitated Spy1 from U-2 OS cells over-

expressing Spy1 and treated with 50 J/m2 of UV for 12 hours or over-expressing p53.
Autoradiograph image corresponding to immuno-precipitated radio-incorporated Spy1
was prepared by exposing the membrane to a tritium-sensitive phosphor-imaging screen,
and bands were quantified with the OptiQuant software. Below each autoradiograph band
is the corresponding Spy1 band after incubating the same membrane with c-Myc
antibody. The right panel presents quantitative analysis of the data from the
autoradiograph bands, normalized to Myc-Spy1 levels. N=1.
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4.3.2 Phosphorylation of Spy1 by Chk1 and Chk2 following UV irradiation.
As degradation of Spy1 lies downstream of Chk1 and Chk2 kinases (Figure 2.3),
we reasoned that these kinases might be candidate kinases to phosphorylate and downregulate Spy1 protein. A search for the preferential consensus sequence of Chk2
(LXRXXS/T) [11,12] within Spy1 identified one possible phosphorylation site located at
serine 222 (Figure 4.2A). Using the Kinase-specific Phosphorylation Site Prediction
(GPS) software, we also identified six additional potential phosphorylation sites on Spy1
for Chk1 and Chk2 kinases (Figure 4.2A). We performed site-directed mutagenesis to
alter the appropriate residues to non-phosphorylatable alanines (Tables 4.1). We then
transfected U-2 OS cells with the potential Chk1/2 non-phosphorylatable mutants, and
UV treated the cells for 24 hours (Figure 4.2B). Western blot and statistical analysis of
the samples revealed that, indeed, none of the mutations had a significant effect on the
stability of Spy1 protein as all were significantly degraded 24 hours post irradiation
(Figure 4.2B). Although we did not observe a significant stability in any of the Spy1
mutants, the specific contributions of these sites to Spy1 turn over remains to be tested.
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A.

B.

Figure 4.2 Degradation of potential Chk1/2 non-phosphorylatable Spy1 mutants.
A. Schematic representation of potential Chk1 and Chk2 phosphorylation sites on Spy1
protein. B. U-2 OS cells were transfected with potential Chk1/2 non-phosphorylatable
Spy1 mutants. 24 hours after transfection, cells were left untreated or treated with 50 J/m2
of UV and incubated for an additional 24 hour at 37°C. Cells were lysed and then
subjected to immune-blotting. Densitometry of N=3 (right panels) is shown as mean ±
SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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4.4 Discussion
We previously (see Chapter 2) proposed a model in which, following UV
irradiation and p53 activation, Spy1 is degraded and its degradation is dependent on
Chk/p53 pathway. Degradation of Spy1 protein by the E3 ligase Nedd4 (neural precursor
cell expressed developmentally down-regulated protein 4) during normal cell cycle is
well-established to require phosphorylation at critical residues in N-terminus of the
protein [10]. Alternatively, Spy1 has been shown to be targeted for degradation via the
SCFSkp2 (Skp, cullin, F-box) ubiquitin ligase complex [13], which requires substrate
phosphorylation prior to recognition [14,15]. Although we did not assess the possibility
of Spy1 degradation via Nedd4 or the SCFSkp2 complex following UV irradiation, we
observed that Spy1 degradation could be proteosome dependent (Figure 2.2), suggesting
the possibility of its phosphorylation prior to its degradation. As degradation of Spy1 lies
downstream of Chk1 and Chk2 kinases (Figure 2.5), we reasoned that these kinases
might be the candidate kinases to provide the adequate phosphorylation of the protein
which targets the protein for degradation. [32P]-orthophosphate labeling of Spy1
illustrated that net phosphorylation of immune-precipitated Spy1 was increased following
UV exposure and in the presence of high levels of p53 (Figure 4.1). This suggests that,
indeed, Spy1 protein is phosphorylated as a result of DDR activation. However,
additional examinations are required to draw a solid conclusion. To determine whether
Spy1 was phosphorylated as a result of Chk1/2 activation, potential phosphorylation sites
on Spy1 for Chk1 and Chk2 kinases, as predicted by GPS software, were mutated to nonphosphorylatable alanines. None of these substitutions, however, had any significant
effect on the stability of the protein, which suggests that none of these sites are critical
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residues involved in degradation of Spy1 protein following UV irradiation. However, the
cooperativity and redundancy within the targeted residues and/or amongst other sites
might be the reason that none of the sites were of high significance. Whether any of these
residues might be phosphorylated directly by Chk1 or Chk2, incubation of recombinant
Chk1 or Chk2 with the wild-type Spy1 protein, or either of the mutants, followed by
analysis of in vitro phosphorylated Spy1 will provide the answer. To determine the
modified residues in vivo prior to DDR-dependent degradation, ectopically expressed
Spy1 protein can be affinity purified from non-irradiated or UV irradiated cells. Purified
wile-type and mutant Spy1 proteins can be subjected to LC-MS/MS (electrospray
ionization tandem mass spectrometry) to evaluate the phosphorylation status of various
residues.
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Chapter 5: General Discussion and Future Directions
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5.1 Overview and perspectives
Cells constantly encounter intrinsic and extrinsic stressors that can ultimately lead
to DNA damage. The correct response of the cell, in the face of DNA damage, is crucial
to maintain genomic integrity and stability, ensuring faithful transmission of genetic
information to progeny cells. The cellular gatekeeper p53 is responsive to a variety of
DNA stresses. When stimulated, p53 transactivates many target genes implicated in cell
cycle arrest, DNA damage repair, senescence, and apoptosis [1]. The product of one of
these genes, p21, plays a key role in both temporary and permanent cell cycle arrest;
therefore, expression and activity of p21 must be strictly regulated [2-6]. As part of
cellular response to different stimuli, such as DNA damage and dysfunctional telomeres,
p21 directly inhibits the activity of the cyclin E/Cdk2 complex to suppress any further
progress of the cell cycle [2,7]. Unlike cyclin/Cdk complexes, however, Spy1-bound Cdk
is more resistant to the repressive functions of the cyclin-dependent kinase inhibitors
(CKIs) [8-10], capable of bypassing cell cycle checkpoint when damage is occurred.
This work, in part, has focused on the regulation of Spy1 protein as part of the
DNA damage response (DDR). Initially, we dissected the cellular expression pattern of
endogenous Spy1 protein following UV irradiation. Upon damage, abundance of Spy1
immediately declined at the protein level, which then was stabilized to normal levels
within hours of the response, representing a biphasic expression. In normal cycling cells,
Spy1 protein is degraded in an ubiquitin/proteasome-dependent manner [11,12].
Following UV irradiation, application of proteasome inhibitors restored ectopicallyexpressed Spy1 protein levels, further confirming the post-translational regulation of
Spy1. However, our findings do not exclude the possibility of Spy1 degradation via a
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proteasome-independent mechanism, as endogenous Spy1 could only be partially rescued
by MG132 treatment following UV damage (see Figure 5.1). Involvement of other
cellular proteolytic processes, such as lysosomal degradation, calpain-mediated
degradation, and Caspase-induced cleavage, in Spy1 degradation is required to be
evaluated.
Different components of the DDR were targeted to assess their involvement in
degradation of Spy1 protein. Ectopic expression of the checkpoint kinases, Chk1 and
Chk2, depleted Spy1 levels in cells. Inhibition of the activity of either of the kinases,
however, revealed that Chk2 is the kinase necessary for Spy1 degradation, as Spy1
remained stable following UV irradiation in cells treated with a specific Chk2 inhibitor.
DNA damage regulation of Spy1 protein appears to also be dependent on the tumor
suppressor p53, as endogenous levels of Spy1 were inversely expressed to DNA damageinduced activated p53. A transcriptional target of p53, Skp2 (S-phase kinase-associated
protein 2), is known to mediate ubiquitination and degradation of Spy1 [13]. We
hypothesize that p53-mediated degradation of Spy1 may occur via its interaction with
Skp2 (see Figure 5.1). Although we found p53 is required for Spy1 degradation, overexpressed Spy1 responded differently in cells lacking the tumor suppressor p53 or both
p53 and Rb. Absence of Rb in p53 null background facilitated degradation of Spy1 in
response to damage; this suggests that Rb/E2F, possibly, regulate expression of a protein,
or a subset of them, that is required for Spy1 degradation. Our data suggests that the
molecular mechanism of Spy1 degradation following UV irradiation is more complex
than that of a simple event. Further work is needed to investigate whether checkpoint
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kinases require p53 to down-regulate Spy1 and how p53 and Rb cooperate to modulate
Spy1 degradation.
To understand the requirement of Spy1 degradation, our work was expanded to
focus on fundamental consequences of Spy1 misregulation. As a Cdk partner, Spy1
accelerates cell growth and proliferation [14], hallmarks of cancer cells. Here, we
observed that when cells were exposed to UV irradiation or undergoing replicative
senescence, over-expression of Spy1 induced a higher tolerance threshold for the
stimulus and cells survived longer. These results highlight the essentiality of targeted
down-regulation of Spy1 for the adequate cellular response to those stimuli triggering
checkpoint activation, such as DNA damage and short dysfunctional telomeres.
Abrogation of this targeted degradation overrides protective checkpoint barriers,
promotes survival and proliferation of damaged cells, and may represent potentially
deleterious consequences to the organism.
It is well-established that the oncogenic transcription factor c-Myc is able to
stabilize the tumor suppressor p53 by inducing the expression of the ARF (alternative
reading frame) protein [15]. Additionally, c-Myc can negatively regulate p21 expression
[16-18]. By inhibition of p21 expression, c-Myc positively regulates the G1 phasespecific cyclin E/Cdk2 complex [19], thereby suppressing senescence [20,21]. It has been
previously reported that Spy1 is a downstream target of MAPK (mitogen-activated protein
kinase) and c-Myc signaling [22]. Our data here suggests a very similar role for Spy1 in

suppressing stress-induced senescence. Ectopic expression of Spy1 stabilized p53 and
induced its activation. Whether, similar to c-Myc, Spy1-induced stability of p53 protein
is due to induction of expression of ARF protein and therefore inhibition of Mdm2, needs
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to be investigated (see Figure 5.1). Unlike the c-Myc onco-protein, Spy1 did not have the
ability to inhibit the mRNA expression of p21. However, cells over-expressing Spy1,
when faced to high levels of p53, or activated p53 following UV irradiation and/or
replicative senescence, were more resistant to anti-proliferative signals. To impose its
proliferative/anti-senescence effect, Spy1 requires the presence of both p53 and p21. Our
evidence shows that Spy1 stimulates p21 degradation. Spy1 interacts with the Cdk2/p21
complex and inhibits p21 function, leading to Cdk2 activation (see Figure 5.1). To
conclusively relate these effects of Spy1 to senescence, phosphorylation status of the
retinoblastoma protein (Rb), a very significant regulator of senescence, needs to be
assessed.
Reduced levels of Spy1 have been shown to decrease cell proliferation following
UV irradiation [23]. Here, we illustrate that depletion of Spy1 protein caused a more
rapid onset of replicative senescence. This further highlights the importance of Spy1
expression in maintaining the proliferation capacity of mammalian cells. In mammalian
cell systems the amount of complexity is highly elevated, which requires a high degree of
programming. Therefore, cells have evolved to employ numerous specialized complexes
to regulate their activities. For instance, cells express several Cdks to control their
proliferation; however, this is not achieved without the help of cyclins. Although cyclins
are the main regulators of Cdks, to obtain more specialized functions, atypical cyclins
such as Spy1 are required. However, this level of regulation appears not to be required in
less developed organisms such as yeast, where even a very limited number of cyclin/Cdk
complexes are sufficient to drive cell cycle progression.
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In conclusion, our work has contributed to the understanding of the requirement
for critical regulation of Spy1 for proper cellular response to DNA damage and during
replicative senescence. We establish Spy1 as a mediator of cellular senescence, a
mechanism that is decisive for cellular response to DNA damage or dysfunctional
telomeres. We further investigate the molecular mechanism of Cdk2 activation by Spy1
and represent Spy1 as a unique regulator of the cyclin-dependent kinase inhibitor p21.
Further determination of the underlying mechanism may provide important information
for treatment of subsets of cancers with elevated Spy1 expression.
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Figure 5.1 Spy1 in DNA damage response pathway.
An overall perspective is presented on degradation of Spy1 by DDR and the role of Spy1
in regulating cell cycle in response to DNA damage, thereby affecting cell cycle
progression and senescence. See text for detailed discussion.
P: phosphorylation, Ub: ubiquitin.
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Appendices
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Appendix 1. Construction of SPDYA mutant constructs.
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Appendix 1.1 Miscellaneous mutants.
T10A:
Oligo number
A309
A310

Sequence
5'-CAGATGTGTTGTGAGGCGCCACCTACTGTCACTG-3'
5'-CAGTGACAGTAGGTGGCGCCTCACAACACATCTG-3'

T10E:
Oligo number
A311
A312

Sequence
5'-GCACAATCAGATGTGTTGTGAGGAGCCACCTACTGTCACT
GTTTATG-3'
5'-CATAAACAGTGACAGTAGGTGGCTCCTCACAACACATCT
GATTGTGC-3'

T10A/P12A:
Oligo number
A313
A314

Sequence
5'-AATCAGATGTGTTGTGAGGCACCAGCTACTGTCACTGTTT
ATG-3'
5'-CATAAACAGTGACAGTAGCTGGTGCCTCACAACACATCT
GATT-3'

N42K:
Oligo number
B271
B272

Sequence
5'-ACTCTGAAGCGTCCTATTTGTAAAGATAAGTGGCAAGCAT
TTGAA-3'
5'-TTCAAATGCTTGCCACTTATCTTTACAAATAGGACGCTTC
AGAGT-3'

S56A:
Oligo number
A761
A762

Sequence
5'-AAAAAATACACATAATAACAACAAAGCTAAACGCCCCAA
AGGACCTT-3'
5'-AAGGTCCTTTGGGGCGTTTAGCTTTGTTGTTATTATGTGTA
TTTTTT -3'
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Appendix 1.2 Potential non-Cdk binding mutants.
D136A/E137A/E138A:
Oligo number
B007
B008

Sequence
5'-TATCTGGCTAATACAGTTGAAGAAGCTGCAGCAGAAACC
AAGTACGAAATTTTTCCA-3'
5'-GGAAAAATTTCGTACTTGGTTTCTGCTGCAGCTTCTTCAA
CTGTATTAGCCAGATA-3'

E134A/E135A/D136A/E137A/E138A/E139A:
Oligo number
B007
B008
B019
B020

Sequence
5'-TATCTGGCTAATACAGTTGAAGAAGCTGCAGCAGAAACC
AAGTACGAAATTTTTCCA-3'
5'-GGAAAAATTTCGTACTTGGTTTCTGCTGCAGCTTCTTCAA
CTGTATTAGCCAGATA-3'
5'-GTATCTGGCTAATACAGTTGCAGCAGCTGCAGCAGCAAC
CAAGTACGAAATTTTTC-3'
5'-GAAAAATTTCGTACTTGGTTGCTGCTGCAGCTGCTGCAAC
TGTATTAGCCAGATAC-3'

D90A/D136A/E137A/E138A:
Oligo number
B007
B008

Sequence
5'-TATCTGGCTAATACAGTTGAAGAAGCTGCAGCAGAAACC
AAGTACGAAATTTTTCCA-3'
5'-GGAAAAATTTCGTACTTGGTTTCTGCTGCAGCTTCTTCAA
CTGTATTAGCCAGATA-3'

D90A/E134A/E135A/D136A/E137A/E138A/E139A:
Oligo number
B007
B008
B019
B020

Sequence
5'-TATCTGGCTAATACAGTTGAAGAAGCTGCAGCAGAAACC
AAGTACGAAATTTTTCCA-3'
5'-TGGAAAAATTTCGTACTTGGTTTCTGCTGCAGCTTCTTCA
ACTGTATTAGCCAGATA-3'
5'-GTATCTGGCTAATACAGTTGCAGCAGCTGCAGCAGCAAC
CAAGTACGAAATTTTTC-3'
5'-GAAAAATTTCGTACTTGGTTGCTGCTGCAGCTGCTGCAAC
TGTATTAGCCAGATAC-3'
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Appendix 2. Construction of Flag-SPDYA-pTRE-Tight.
Oligos to create a restriction site for XbaI enzyme in Flag-SPDYA-plXSN:
Oligo number
A504
A505

Sequence
5'-AAGGTATGATATAGTAATATGCCAGATCTAGATTTATGCA
TGTTGTTTACTGAGC-3'
5'-CTCAGTAAACAACATGCATAAATCTAGATCTGGCATATTA
CTATATCATACCTTC-3'

Digestion of pTRE-Tight caspase-3 construct using EcoRI and XbaI restriction enzymes:

Ligation of EcoRI-Flag-SPDYA-XbaI fragment into the digested pTRE-Tight plasmid:
AATTCGCGGCCGCGTCGACCTGCGACGGAGCCTTGACCGCCGTTGCCCGGCC
CTCTCCCGCGCAGCCCCGGGCTTCCGCAGGAATATTGGGAAACCCATATGGA
CTACAAAGACCATGACGGTGATTATAAAGATCATGATATCGATTACAAGGAT
GACGATGACAAGAGGCACAATCAGATGTGTTGTGAGACACCACCTACTGTCA
CTGTTTATGTAAAATCAGGGTCAAATAGATCACATCAGCCTAAAAAGCCCAT
TACTCTGAAGCGTCCTATTTGTAAAGATAATTGGCAAGCATTTGAAAAAAAT
ACACATAATAACAACAAATCTAAACGCCCCAAAGGACCTTGTCTGGTTATAC
AGCGTCAGGATATGACTGCTTTCTTTAAATTATTTGATGACGATTTAATTCAA
GATTTCTTGTGGATGGACTGCTGCTGTAAAATTGCAGACAAGTATCTTTTGGC
TATGACCTTTGTTTATTTCAAGAGGGCTAAATTTACTATAAGTGAGCATACCA
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GGATAAATTTCTTTATTGCTCTGTATCTGGCTAATACAGTTGAAGAAGATGAA
GAAGAAACCAAGTACGAAATTTTTCCATGGGCTTTAGGGAAAAACTGGAGAA
AATTGTTCCCTAATTTCTTAAAGTTAAGGGACCAGCTCTGGGATAGAATTGAC
TATAGGGCTATTGTAAGCAGGCGATGTTGTGAGGAGGTTATGGCCATTGCAC
CAACCCATTATATCTGGCAAAGAGAACGTTCTGTTCATCACAGTGGAGCTGTC
AGAAACTACAACAGAGATGAAGTTCAGCTGCCCCGGGGACCTAGTGCCACAC
CAGTAGATTGTTCACTCTGTGGTAAAAAAAGAAGATATGTTAGACTGGGATT
GTCTTCATCATCATCTTTATCCAGTCATACAGCAGGGGTGACAGAAAAACATT
CTCAGGACTCATACAACTCACTGTCAATGGACATAATAGGTGATCCTTCTCAA
GCTTATACTGGTTCTGAAGGTATGATATAGTAATATGCCAGAATTAGATTTAT
GCATGTTGTTTACTGAGCTCTAGTCAGTCCTTTCTGGCGGGGATACATAATAA
TTTATATACTCCAACAATATGAGTTAAATTAATCTTGAAACTTTCTCCCCTTTC
AGTTACTTTTTGTCTTGTGTCCATATTTGTTTTGTGGTGACCCACCTAAACAGA
TTTTTAATGTGACCTATGTTAAGTTGAAAACTAATGCACCATAAGCCTCAGTA
TTTTAAGAGCCTGAATCATTTTTTTGAAATGTTTATTTTATTCAAAAGGGTTTC
AAGAAGAAAATAAATTTACTTGTAATCTCAAAAAAAAAAAAAAAAAAAAAA
TCTAG
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Genotyping oligos:
Oligo number
A548
A549
A550

Sequence
5'-ATCAGTGATAGAGAACGATGTCGAGT-3'
5'-TTGTGCCTCTTGTCATCGTCAT-3'
5'-GTCATAGCCAAAAGATACTTGTCTGC-3'

Oligo number
A718

Sequence
5'-GGTGGGAGGCCTATATAAGCAGAGCTCGTTTAG-3'

A719

5'-CAAAGGTCATAGCCAAAAGATACTTGTCTGCAATTTTACAGC
A-3'

Oligo number
A754

Sequence
5'-GGCGATGTTGTGAGGAGGTTATGGCCATTGCAC-3'

A755

5'-CTGAGGCTTATGGTGCATTAGTTTTCAACTTAACATAGGTCAC
A-3'

Oligo number
A756
A757

Sequence
5'-TATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCG-3'
5'-CAAAGGTCATAGCCAAAAGATACTTGTCTGCAATTTTACAGCA
GC-3'

Oligo number
A779
A780

Sequence
5'-GTGTACGGTGGGAGGCCTATATAA-3'
5'-CCATATGGGTTTCCCAATATTCCT-3'

Oligo number
A781
A782

Sequence
5'-GATTACAAGGATGACGATGACAAGA-3'
5'-GACGCTTCAGAGTAATGGGCTT-3'

Oligo number
A801
A802

Sequence
5'-GACCTGCGACGGAGCCTT-3'
5'-CGTCATCCTTGTAATCGATATCATGA-3'
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Appendix 3. Construction of inducible knock-down and over-expression constructs
for SPDYA.

sh SPDYA 259:
Oligo
number
B099

B100

Sequence
5'-TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCGTGGATG
GACTGCTGCTGTAATAGTGAAGCCACAGATGTATTACAGCA
GCAGTCCATCCACATGCCTACTGCCTCGG-3'
5'-AATTCCGAGGCAGTAGGCATGTGGATGGACTGCTGCTGTA
ATACATCTGTGGCTTCACTATTACAGCAGCAGTCCATCCACG
CGCTCACTGTCAACAGCAATATACCTTC-3'

sh SPDYA 302:
Oligo
number
B101

B102

Sequence
5'-TCGAGAAGGTATATTGCTGTTGACAGTGAGCGAGCTATGA
CCTTTGTTTATTTCTAGTGAAGCCACAGATGTAGAAATAAAC
AAAGGTCATAGCCTGCCTACTGCCTCGG-3'
5'-AATTCCGAGGCAGTAGGCAGGCTATGACCTTTGTTTATTTC
TACATCTGTGGCTTCACTAGAAATAAACAAAGGTCATAGCTC
GCTCACTGTCAACAGCAATATACCTTC-3'
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Appendix 4. Construction of human CHK1, CHK2, CCNE1 and SPDYA knock-down
constructs.
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CHK1:
Oligo number
A826
A827

Sequence
5'-CCGGAACTTCTGAAGAGAAGAGAATCTCGAGATTCTCTTC
TCTTCAGAAGTTTTTTTG-3'
5'-AATTCAAAAAAACTTCTGAAGAGAAGAGAATCTCGAGAT
TCTCTTCTCTTCAGAAGTT-3'

CHK2 #1:
Oligo number
B009
B010

Sequence
5'-CGGGAGGACTGTCTTATAAAGATTCTCGAGTCTTTATAAG
ACAGTCCTCTTTTTTTG-3'
5'-AATTCAAAAAAAGAGGACTGTCTTATAAAGACTCGAGAA
TCTTTATAAGACAGTCCTC-3'

CHK2 #2:
Oligo number
B011
B012

Sequence
5'-CCGGCGGTATTATACACCGTGACTTCTCGAGGTCACGGTG
TATAATACCGTTTTTTTG-3'
5'-AATTCAAAAAAACGGTATTATACACCGTGACCTCGAGAA
GTCACGGTGTATAATACCG-3'

CHK2 #3:
Oligo number
B013
B014

Sequence
5'-CCGGGAACAGATAAATACCGAACATCTCGAGATGTTCGG
TATTTATCTGTTCTTTTTG-3'
5'-AATTCAAAAAGAACAGATAAATACCGAACATCTCGAGAT
GTTCGGTATTTATCTGTTC-3'

CCNE1 #1:
Oligo number
A783
A784

Sequence
5'-CCGGGTGCTGCTATATCTATCCATTCTCGAGTGGATAGAT
ATAGCA GCACTTTTTTTG-3'
5'-AATTCAAAAAAAGTGCTGCTATATCTATCCACTCGAGAAT
GGATAGATATAGCAGCAC-3'
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CCNE1 #2:
Oligo number
A785
A786

Sequence
5'-CCGGAATGCGAGCAATTCTTCTGGACTCGAGTCCAGAAG
AATTGCTCGCATTTTTTTG-3'
5'-AATTCAAAAAAATGCGAGCAATTCTTCTGGACTCGAGTCC
AGAAGAATTGCTCGCATT-3'

SPDYA #1:
Oligo number
B001
B002

Sequence
5'-CCGGTGAGGCACAATCAGATGTGTTCTCGAGAACACATCT
GATTGTGCCTCATTTTTG-3'
5'-ATTCAAAAATGAGGCACAATCAGATGTGTTCTCGAGAAC
ACATCTGATTGTGCCTCA-3'

SPDYA #2:
Oligo number
B003
B004

Sequence
5'-CCGGTGGACATAATAGGTGATCCTTCTCGAGAAGGATCA
CCTATTATGTCCATTTTTG-3'
5'-AATTCAAAAATGGACATAATAGGTGATCCTTCTCGAGAA
GGATCACCTATTATGTCCA-3'

SPDYA #3:
Oligo number
B005
B006

Sequence
5'-CCGGTAGGTGATCCTTCTCAAGCTTCTCGAGAAGCTTGAG
AAGGATCACCTATTTTTG-3'
5'-AATTCAAAAATAGGTGATCCTTCTCAAGCTTCTCGAGAAG
CTTGAGAAGGATCACCTA-3'

SPDYA #4:
Oligo number
B015
B016

Sequence
5'-CCGGGTGAGCATACCAGGATAAATTCTCGAGTTTATCCTG
GTATGCTCACTTTTTTTG-3'
5'-AATTCAAAAAAAGTGAGCATACCAGGATAAACTCGAGAA
TTTATCCTGGTATGCTCAC-3'
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